WO2024026423A1 - Dérivés de quinoléine substitués utiles comme inhibiteurs de pi3k - Google Patents

Dérivés de quinoléine substitués utiles comme inhibiteurs de pi3k Download PDF

Info

Publication number
WO2024026423A1
WO2024026423A1 PCT/US2023/071143 US2023071143W WO2024026423A1 WO 2024026423 A1 WO2024026423 A1 WO 2024026423A1 US 2023071143 W US2023071143 W US 2023071143W WO 2024026423 A1 WO2024026423 A1 WO 2024026423A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
cancer
independently
halogen
Prior art date
Application number
PCT/US2023/071143
Other languages
English (en)
Inventor
Yelena ARNAUTOVA
Etienne DARDENNE
Iwona WRONA
Ivan JEWETT
Istvan J. Enyedy
Fernando Padilla
Matthew C. Lucas
Original Assignee
Black Diamond Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Therapeutics, Inc. filed Critical Black Diamond Therapeutics, Inc.
Publication of WO2024026423A1 publication Critical patent/WO2024026423A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Phosphatidylinositol 3-Kinases are a group of plasma membrane-associated lipid kinases that upon activation catalyze the transfer of phosphate to the D-3' position of inositol of phosphoinositol-4,5-phosphate (PIP2) to produce the second messenger phosphoinositol-3,4,5-phosphate (PIP3).
  • PIP2 phosphoinositol-4,5-phosphate
  • PIP3Ks are known to control and regulate of a variety of different cellular activities, including transcription, translation, proliferation, survival, chemotaxis, motility, cellular trafficking and metabolism.
  • pl 10a also referred to as PI3Ka catalytic subunit
  • PI3Ka pl 10a catalytic subunit
  • cancers including bladder cancer, brain cancer, breast cancer, colon cancer, endometrial cancer, ovarian cancer, skin cancer, stomach cancer, lung cancer and prostate cancer.
  • These mutations include oncogenic gain-of-function mutations that occur within mutation hotspots, primarily within the kinase and helicase domains.
  • pl 10a has been identified as a potential therapeutic- target in the treatment of various cancers and other PI3K-driven diseases.
  • the present disclosure provides a compound of Formula (I): an isomer thereof, or a pharmaceutically acceptable salt thereof, wherein:
  • R 1 is H, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 1 -C 6 haloalkyl;
  • R 2 is H, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;
  • R 4 is H, halogen, cyano, C 1 -C 6 alkyl, Cz-Ce alkenyl, C 2 -C 6 alkynyl, or C 3 -C 12 cycloalkyl;
  • R 5 is C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10- membered heteroaryl, wherein the C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, Ce- C 10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R 5a ; each R 5a independently is halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, Cz-Ce alkynyl, C 1 -C 6 alkoxyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl is optional
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
  • the present disclosure provides an intermediate as described herein, being suitable for use in a method for preparing a compound as described herein (e.g., the intermediate is selected from the intermediates described in Examples 1-62).
  • the present disclosure provides a method of modulating PI3Ka activity (e.g., in vitro or in vivo), comprising contacting a cell with an effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in modulating PI3 Ka activity (e.g., in vitro or in vivo).
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease or disorder disclosed herein.
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder disclosed herein.
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for modulating PI3Ka activity (e.g., in vitro or in vivo).
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or disorder disclosed herein.
  • the present disclosure provides a method of preparing a compound of the present disclosure.
  • the present disclosure provides a method of preparing a compound, comprising one or more steps described herein.
  • the present disclosure relates to substituted quinoline derivatives, prodrugs, and pharmaceutically acceptable salts thereof, which may modulate PI3Ka activity and are accordingly useful in methods of treatment of the human or animal body.
  • the present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them and to their use in the treatment of disorders in which PI3Ka is implicated, such as cancer.
  • alkyl As used herein, “alkyl”, “Ci, Cb, Cs, Ch, Cs or Cs alkyl” or “Ci-C 6 alkyl” is intended to include Ci, C2, C3, C4, Cs or Cs straight chain (linear) saturated aliphatic hydrocarbon groups and Cs, C4, Cs or Ce branched saturated aliphatic hydrocarbon groups.
  • C r C 6 alkyl is intends to include C b C 2 , C 3 , C 4 , C 5 and C 6 alkyl groups.
  • alkyl examples include, moieties having from one to six carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, or n-hexyl.
  • a straight chain or branched alkyl has six or fewer carbon atoms (e.g., C 1 -C 6 for straight chain, Cs-Ce for branched chain), and in another embodiment, a straight chain or branched alkyl has four or fewer carbon atoms.
  • optionally substituted alkyl refers to un substituted alkyl or alkyl having designated substituents replacing one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl , alkylaminocarbonyl , dialkylaminocarbonyl, alkylthiocarbonyl , alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino), acylamino (including alky
  • alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
  • alkenyl includes straight chain alkenyl groups (e.g, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl), and branched alkenyl groups.
  • a straight chain or branched alkenyl group has six or fewer carbon atoms in its backbone (e.g, C 2 -C 6 for straight chain, Cj-Ce for branched chain).
  • C 2 -C 6 includes alkenyl groups containing two to six carbon atoms.
  • Cs-Ce includes alkenyl groups containing three to six carbon atoms.
  • optionally substituted alkenyl refers to unsubstituted alkenyl or alkenyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, aminocarbonyl, alkylaminocarbonyl, dial ky I aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, ary I carbonyl ami no, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, s
  • alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
  • alkynyl includes straight chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl), and branched alky nyl groups.
  • a straight chain or branched alkynyl group has six or fewer carbon atoms in its backbone (e.g, C 2 -C 6 for straight chain, C3-C6 for branched chain).
  • C 2 -C 6 includes alkynyl groups containing two to six carbon atoms.
  • C3- C& includes alkynyl groups containing three to six carbon atoms.
  • C 2 -C 6 alkenylene linker” or “C 2 -C 6 alkynylene linker” is intended to include C2, Cb, Cr, C5 or Co chain (linear or branched) divalent unsaturated aliphatic hy drocarbon groups.
  • C 2 - C 6 alkenylene linker is intended to include C2, C3, C4, Cs and Co alkenylene linker groups.
  • optionally substituted alkynyl refers to unsubstituted alkynyl or alkynyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxy carbonyl oxy, aryloxycarbonyloxy, carboxylate, alkyl carbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alky I ami nocarbonyl, dial kylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
  • optionally substituted nioieties include both the unsubstituted moieties and the moieties having one or more of the designated substituents.
  • substituted heterocycloalkyl includes those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl- piperidinyl and 2,2,6,6-tetramethyl-l,2,3,6-tetrahydropyridinyl.
  • cycloalkyl refers to a saturated or partially unsaturated hydrocarbon monocyclic or polycyclic (e.g., fused, bridged, or spiro rings) system having 3 to 30 carbon atoms (e.g., C 3 -C 12 , C3-C10, or Cr-Cs).
  • cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, and adamantyl.
  • cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthalenyl, and adamantyl.
  • polycyclic cycloalkyl only one of the rings in the cycloalkyl needs to be nonaromatic.
  • heterocycloalkyl refers to a saturated or partially unsaturated 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged, or spiro rings), or 11 -14 membered tricyclic ring system (fused, bridged, or spiro rings) having one or more heteroatoms (such as O, N, S, P, or Se), e.g., 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g. s 1, 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur, unless specified otherwise.
  • heteroatoms such as O, N, S, P, or Se
  • heterocycloalkyl groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolidinyl, dioxanyl, tetrahydrofuranyl, isoindolinyl, indolinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, 1, 2,3,6- tetrahydropyridinyl, tetrahydropyranyl, di hydropyranyl, pyranyl, morpholinyl, tetrahydrothiopyranyl, 1,4-diazepanyl, 1,4-oxazepanyl, 2-oxa-5-azabicyclo[2.2.
  • heterocycloalkyl In the case of multicyclic heterocycloalkyl, only one of the rings in the heterocycloalkyl needs to be non-aromatic (e.g., 4, 5,6,7- tetrahydrobenzo[c]isoxazolyl).
  • variable X cycloalkyl or heterocycloalkyl
  • the two attachments could be at the same atom or different atoms of the cycloalkyl or heterocycloalkyl.
  • aryl includes groups with aromaticity, including “conjugated,” or multicyclic systems with one or more aromatic rings and do not contain any heteroatom in the ring structure.
  • aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like.
  • heteroaryl is intended to include a stable 5-, 6-, or 7- membered monocyclic or 7-, 8 ⁇ , 9-, 10-, 11- or 12-membered bicyclic aromatic heterocyclic ring which consists of carbon atoms and one or more heteroatoms, e.g., 1 or 1-2 or 1 -3 or 1-4 or 1-5 or 1-6 heteroatoms, or e.g , 1, 2, 3, 4, 5, or 6 heteroatoms, independently selected from the group consisting of nitrogen, oxygen and sulfur.
  • the nitrogen atom may be substituted or unsubstituted (i.e., N or NR wherein R is H or other substituents, as defined).
  • the nitrogen and sulfur heteroatoms may optionally be oxidised (/. ⁇ ?., N— >0 and S(O)p, where p :::: 1 or 2). It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like.
  • Heteroaryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multi cyclic system (e.g, 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).
  • the heteroaryl is thiophenyl or benzothiophenyl.
  • the heteroaryl is thiophenyl.
  • the heteroaryl benzothiophenyl.
  • aryl and heteroaryl include multi cyclic aryl and heteroaryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
  • tricyclic, bicyclic e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, deazapurine, indolizine.
  • the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring can be substituted at one or more ring positions (e.g., the ring-forming carbon or heteroatom such as N) with such substituents as described above, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carb oxy 1 ate, al ky I carb ony I , al ky I aminocarb ony 1 , aralkyl ami nocarb ony I , alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxy carbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinate, amino (
  • Aryl and heteroaryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedi oxyphenyl such as benzo[d][l ,3]dioxole-5-yl).
  • alicyclic or heterocyclic rings which are not aromatic so as to form a multicyclic system (e.g., tetralin, methylenedi oxyphenyl such as benzo[d][l ,3]dioxole-5-yl).
  • substituted means that any one or more hydrogen atoms on the designated atom is replaced with a selection from the indicated groups, provided that the designated atom’s normal valency is not exceeded, and that the substitution results in a stable compound.
  • 2 hydrogen atoms on the atom are replaced.
  • Keto substituents are not present on aromatic rnoieties.
  • “Stable compound” and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • any variable e.g., R
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • R e.g., R
  • the group may optionally be substituted with up to two R rnoieties and R at each occurrence is selected independently from the definition of R.
  • substituents and/or variables are permissible, but only if such combinations result in stable compounds.
  • hydroxy or “hydroxyl” includes groups with an -OH or -O"
  • halo refers to fluoro, chloro, bromo and iodo.
  • haloalkyl or haloalkoxyl refers to an alkyl or alkoxyl substituted with one or more halogen atoms.
  • optionally substituted haloalkyl refers to unsubstituted haloalkyl having designated substituents replacing one or more hydrogen atoms on one or more hydrocarbon backbone carbon atoms.
  • substituents can include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, aryl carbonyl oxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkyl carbonyl, aryl carbonyl, alkoxycarbonyl, aminocarbonyl, alkyl aminocarbonyl, dialkyl aminocarbonyl, alkyl thiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diaryl amino and alkylarylamino), acylamino (including alkyl carbonyl ami no, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sul
  • alkoxy' or “alkoxy!” includes substituted and unsubstituted alkyl, alkenyl and alkynyl groups covalently linked to an oxygen atom.
  • alkoxy groups or alkoxyl radicals include, but are not limited to, methoxy, ethoxy, isopropyloxy, propoxy, butoxy and pentoxy groups.
  • substituted alkoxy groups include halogenated alkoxy groups.
  • the alkoxy groups can be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxy carbonyl oxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl , alkylaminocarbonyl , dialkylaminocarbonyl, alkylthiocarbonyl , alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkyl arylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarbox
  • the expressions “one or more of A, B, or C,” “one or more A, B, or C,” “one or more of A, B, and C,” “one or more A, B, and C,” “selected from the group consisting of A, B, and C”, “selected from A, B, and C”, and the like are used interchangeably and all refer to a selection from a group consisting of A, B, and/or C, i.e., one or more As, one or more Bs, one or more Cs, or any combination thereof, unless indicated otherwise.
  • the present disclosure provides methods for the synthesis of the compounds of any of the Formulae described herein.
  • the present disclosure also provides detailed methods for the synthesis of various disclosed compounds of the present disclosure according to the following schemes as well as those shown in the Examples.
  • compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously.
  • any description of a method of treatment or prevention includes use of the compounds to provide such treatment or prevention as is described herein. It is to be further understood, unless otherwise stated, any description of a method of treatment or prevention includes use of the compounds to prepare a medicament to treat or prevent such condition.
  • the treatment or prevention includes treatment or prevention of human or non-human animals including rodents and other disease models.
  • any description of a method of treatment includes use of the compounds to provide such treatment as is described herein. It is to be further understood, unless otherwise stated, any description of a method of treatment includes use of the compounds to prepare a medicament to treat such condition.
  • the treatment includes treatment of human or non-human animals including rodents and other disease models.
  • the term “subject” includes human and non-human animals, as well as cell lines, cell cultures, tissues, and organs.
  • the subject is a mammal.
  • the mammal can be e.g., a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep or a pig.
  • the subject can also be a bird or fowl.
  • the subject is a human.
  • the term “subject in need thereof’ refers to a subject having a disease or having an increased risk of developing the disease.
  • a subject in need thereof can be one who has been previously diagnosed or identified as having a disease or disorder disclosed herein.
  • a subject in need thereof can also be one who is suffering from a disease or disorder disclosed herein.
  • a subject in need thereof can be one who has an increased risk of developing such disease or disorder relative to the population at large (i.e., a subject who is predisposed to developing such disorder relative to the population at large).
  • a subject in need thereof can have a refractory or resistant a disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that does not respond or has not yet responded to treatment).
  • the subject may be resistant at start of treatment or may become resistant during treatment.
  • the subject in need thereof received and failed all known effective therapies for a disease or disorder disclosed herein.
  • the subject in need thereof received at least one prior therapy.
  • the term “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the present disclosure, or a pharmaceutically acceptable salt, polymorph or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.
  • the term “treat” can also include treatment of a cell w? vitro or an animal model. It is to be appreciated that references to “treating” or “treatment” include the alleviation of established symptoms of a condition.
  • Treating” or “treatment” of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the state, disorder or condition, i.e., arresting, reducing or delaying the development of the disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
  • a compound of the present disclosure can or may also be used to prevent a relevant disease, condition or disorder, or used to identify suitable candidates for such purposes.
  • the term “preventing,” “prevent,” or “protecting against” describes reducing or eliminating the onset of the symptoms or complications of such disease, condition or disorder.
  • compositions comprising any compound described herein in combination with at least one pharmaceutically acceptable excipient, or carrier.
  • the term “’pharmaceutical composition” is a formulation containing the compounds of the present disclosure in a form suitable for administration to a subject.
  • the pharmaceutical composition i s in bulk or in unit dosage form .
  • the unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler or a vial.
  • the quantity of active ingredient (e.g., a formulation of the disclosed compound or salt, hydrate, solvate or isomer thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved.
  • the dosage will also depend on the route of admini station .
  • routes include oral, pulmonary', rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalational, buccal, sublingual, intrapleural, intrathecal, intranasal, and the like.
  • Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
  • the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.
  • the term “pharmaceutically acceptable” refers to those compounds, anions, cations, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • the term “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use.
  • a “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
  • a pharmaceutical composition of the disclosure is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g, ingestion), inhalation, transdermal (topical), and transmucosal administration.
  • Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid, buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity' such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • a compound or pharmaceutical composition of the disclosure can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment.
  • a compound of the disclosure may be injected into the blood stream or body cavities or taken orally or applied through the skin with patches.
  • the dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects.
  • the state of the disease condition (e.g., a disease or disorder disclosed herein) and the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.
  • the term ‘Therapeutically effective amount”, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect.
  • the effect can be detected by any assay method known in the art.
  • the precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration.
  • Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician,
  • the term “therapeutically effective amount”, refers to an amount of a pharmaceutical agent to treat or ameliorate an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect.
  • the effect can be detected by any assay method known in the art.
  • the precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration.
  • Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician.
  • the therapeutically effective amount can be estimated initially either in cell culture assays, e.g, of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs.
  • the animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., EDso (the dose therapeutically effective in 50 % of the population) and LDso (the dose lethal to 50 % of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50.
  • Pharmaceutical compositions that exhibit large therapeutic indices are preferred.
  • the dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. [0072] Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the di sease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every' 3 to 4 days, every week, or once every' two weeks depending on half-life and clearance rate of the particular formulation.
  • compositions containing active compounds of the present disclosure may be manufactured in a manner that is generally known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilising processes.
  • Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), cyclodextrins and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol and sorbitol, and sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilisation.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, capsules or sachets. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid earner is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterot.es; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterot.es
  • a glidant such as colloidal silicon dioxide
  • the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebuliser.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebuliser.
  • Systemic administration can also be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
  • Transmucosal administration can be accomplished through the use of nasal sprays, powders or suppositories.
  • the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the active compounds can be prepared with pharmaceutically acceptable earners that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polygly colic acid, collagen, poly orthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
  • the dosages of the pharmaceutical compositions used in accordance with the disclosure vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage.
  • the dose should be sufficient to result in slowing, and preferably regressing, the symptoms of the disease or disorder disclosed herein and also preferably causing complete regression of the disease or disorder.
  • Dosages can range from about 0.01 mg/kg per day to about. 5000 mg/kg per day.
  • An effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. Improvement in survival and growth indicates regression.
  • the term “dosage effective manner” refers to amount of an active compound to produce the desired biological effect in a subject or cell.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • the term “pharmaceutically acceptable salts” refer to derivatives of the compounds of the present disclosure wherein the parent compound is modified by making acid or base salts thereof
  • pharmaceutically acceptable salts include, but are not limited to, mineral organic acid salts of basic residues such as amines, alkali organic salts of acidic residues such as carboxylic acids, and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic organic acids.
  • such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, 1,2-ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxy maleic, hydroxy naphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric,
  • the pharmaceutically acceptable salt is a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a diethylamine salt, a choline salt, a meglumine salt, a benzathine salt, a tromethamine salt, an ammonia salt, an arginine salt, or a lysine salt.
  • compositions include hexanoic acid, cyclopentane propionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-l -carboxylic acid, 3- phenyl propionic acid, tri methylacetic acid, tertiary butylacetic acid, muconic acid, and the like.
  • the present disclosure also encompasses salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g, an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
  • a metal ion e.g, an alkali metal ion, an alkaline earth ion, or an aluminum ion
  • an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.
  • the ratio of the compound to the cation or anion of the salt can be 1 : 1, or any ratio other than 1 : 1, e.g., 3 : 1, 2: 1, 1 :2, or 1 :3.
  • references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.
  • the compounds, or pharmaceutically acceptable salts thereof are administered orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally and parenterally. In one embodiment, the compound is administered orally.
  • One skilled in the art will recognise the advantages of certain routes of administration.
  • the dosage regimen utilising the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.
  • An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to counter or arrest the progress of the condition.
  • the compounds described herein, and the pharmaceutically acceptable salts thereof are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent.
  • suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous organic solutions.
  • the compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein.
  • compounds may be drawn with one particular configuration for simplicity. Such particular configurations are not to be construed as limiting the disclosure to one or another isomer, tautomer, regioisomer or stereoisomer, nor does it exclude mixtures of isomers, tautomers, regioisomers or stereoisomers; however, it wall be understood that a given isomer, tautomer, regioisomer or stereoisomer may have a higher level of activity than another isomer, tautomer, regioisomer or stereoisomer.
  • the present disclosure provides a compound of Formula (I): an isomer thereof, or a pharmaceutically acceptable salt thereof wherein:
  • R 1 is H, halogen, C 1 -C 6 . alkyl, (h-Cs alkenyl, C 1 -C 6 alkynyl, or C 1 -C 6 haloalkyl;
  • R 2 is H, halogen, cyano, C 1 -C 6 alkyl, Cu-Cs alkenyl, or C 2 -C 6 alkynyl;
  • R 4 is H, halogen, cyano, C 1 -C 6 alkyl, Cu-Ce alkenyl, C 2 -C 6 alkynyl, or C 3 -C 12 cycloalkyl;
  • R 5 is C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, Gs-Cio aryl, or 5- to 10- membered heteroaryl, wherein the C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, Ce- C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R 5a ; each R Sa independently is halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, (k-Cio aryl, or 5- to 10-membered heteroaryl, wherein the Ci-C& alkyl, Cb-Ce alkenyl, C 2 -C 6 alkynyl, C1-C6 alkoxyl, C6-C10 aryl, or 5- to 10-membered heteroaiyl is optionally substituted
  • R 1 is H, halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl
  • R 2 is H, cyano, or C 1 -C 6 alkyl
  • R 4 is H, or C 1 -C 6 alkyl
  • R 5 is 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wh erein the 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R 5a ; each R 5a independently is halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, CG-CJO aryl, or 5- to 10- membered heteroaryl, wherein the C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, CG-CIO aryl, or 5- to 10- membered heteroaryl is optionally substituted with one or more halogen or C 1 -C 6 alkyl;
  • T is -(C 1 -C 6 alkyl)-*, or -(C 1 -C 6 alkyl)-NR r -*, wherein * denotes attachment to A; each R 1 is H; A is C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the C 6 -C 10 aryl, or 5- to 10- membered heteroaryl is optionally substituted with one or more R A ; and each R A independently is -NH2, -('( 0)01 1. -C( :::: O)O(C 1 -C 6 alkyl), or -S( ::::: O)2(C 1 -C 6 alkyl).
  • the present disclosure provides a compound of Formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof, wherein:
  • R 1 is H, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or Ct-Ce haloalkyl;
  • R 2 is H, halogen, cyano, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;
  • R 4 is H, halogen, C1-C& alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl;
  • R 5 is C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10- membered heteroaryl, wherein the C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, Ce- C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R Sa , each R 5a independently is halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C1-C6 alkoxyl, C6-C10 aryl, or 5- to 10-membered heteroaryl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 .
  • alkoxyl, Ce.-Cio aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen or C 1 -C 6 alkyl; alkyl)-*, -(C 1 -C 6 alkyl)-O-*, -O-(C1-C 6 alkyl)-*, -(Ci-C 6 alkyl)-NR T -*, -NR T -(Cr-C 6 alkyl)-*, -(Ci-C 6 haloalkyl)-*, -(Ci-C 6 haloalkyl)-O-*, -O-(C 1 -C 6 haloalkyl)-*, -(C 1 -C 6 .
  • R 1 is H, halogen, C 1 -C 6 alkyl, or C 1 -C 6 . haloalkyl;
  • R 2 is H, cyano, or C 1 -C 6 alkyl
  • R 4 is H, or C1-C6 alkyl
  • R 5 is 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl, wherein the 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R 5a ; each R’ a independently is halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C 6 -C 10 and, or 5- to 10- membered heteroaryl, wherein the C 1 -C 6 alkyl, C 1 -C 6 alkoxyl, C6-C10 and, or 5- to 10- membered heteroaryl is optionally substituted with one or more halogen or C 1 -C 6 alkyl,
  • T is -(C 1 -C 6 alkyl)-*, or -(C 1 -C 6 alkyl)-NR T -*, wherein * denotes attachment to A; each R f is H;
  • variables R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , T, R T , A, R A , and R A1 can each be, where applicable, selected from the groups described herein, and any group described herein for any of variables R j , R 2 , R ⁇ R 4 , R 3 , R 5a , T, R ! , A, R A , and R A1 can be combined, where applicable, with any group described herein for one or more of the remainder of variables R 1 , R 2 , R 3 , R 4 , R’, R 5a , T, R 1 , A, R A , and R A! .
  • R 1 is H, halogen, C1-C6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 1 -C 6 haloalkyl.
  • R f is H, or halogen.
  • R 1 is H. [0103] In some embodiments, R 1 is halogen.
  • R 1 is F, Cl, Br, or I. In some embodiments, R 1 is F, Cl, or Br. In some embodiments, R 1 is F or C1.
  • R 1 is F. In some embodiments, R 1 is Cl. In some embodiments, R l is Br. In some embodiments, R 1 is I.
  • R 1 is C 1 -C 6 alkyl, C 1 -C 6 alkenyl, Cb-Ce alkynyl, or C1-C& haloalkyl.
  • R 1 is C 1 -C 6 alky], or C 1 -C 6 haloalkyl.
  • R 1 is C 1 -C 6 alkyl.
  • R 1 is methyl. In some embodiments, R 1 is ethyl. In some embodiments, R 1 is propyl. In some embodiments, R ! is butyl. In some embodiments, R 1 is pentyl. In some embodiments, R : is hexyl. In some embodiments, R 1 is isopropyl. In some embodiments, R 1 is isobutyl. In some embodiments, R f is isopentyl. In some embodiments, R 1 is isohexyl. In some embodiments, R 1 is secbutyl. In some embodiments, R 1 is secpentyl. In some embodiments, R l is sechexyl. In some embodiments, R 1 is tertbutyl.
  • R 1 is methyl
  • R 1 is C1-C& haloalkyl.
  • R 1 is halomethyl. In some embodiments, R 1 is haloethyl. In some embodiments, R 1 is halopropyl, In some embodiments, R 1 is halobutyl. In some embodiments, R 1 is halopentyl. In some embodiments, R 1 is halohexyl.
  • R 1 is CF?.
  • R 2 is H, halogen, cyano, C1-C& alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl.
  • R 2 is H, halogen, or cyano.
  • R 2 is H, or cyano
  • R 2 is H.
  • R 2 is cyano
  • R 2 is C 1 -C 6 alkyl, C 1 -C 6 alkenyl, or C 2 -C 6 alkynyl.
  • R 2 is Cj-Cfi alkyl.
  • R“ is methyl.
  • R 2 is ethyl.
  • R 2 is propyl.
  • R 2 is butyl.
  • R 2 is pentyl.
  • R 2 is hexyl.
  • R 2 is isopropyl.
  • R 2 is isobutyk
  • R 2 is isopentyl.
  • R 2 is isohexyl.
  • R z is secbutyl.
  • R 2 is secpentyl.
  • R 2 is sechexyl.
  • R 2 is tertbutyl.
  • R 2 is methyl
  • R' r is H, halogen, or cyano.
  • to’ is H.
  • R’ is halogen
  • R 3 is cyano
  • R 3 is C 1 -C 6 alkyl, Cz-Ck alkenyl, or Cz-Ck alkynyl.
  • R’ is Cb-Ck alkynyl.
  • R ' is 3- to 12-membered heterocycloalkyl.
  • R 3 i s morpholinyl .
  • R 3 is ( ( O) ⁇ Hz.
  • R 4 is H, halogen, cyano, C1-C6 alkyl, C 2 -C 6 alkenyl, Cz-Ck alkynyl, or C 3 -C 12 cycloalkyl.
  • R 4 is H, halogen, Ci-Ck alkyl, Cz-Ck alkenyl, Cz-Ck alkynyl, or C 3 -C 12 cycloalkyl.
  • R 4 is H, halogen, Ci-(k alkyl, Cz-Ck alkenyl, or Cz-Ck alkynyl.
  • R 4 is H, halogen, or cyano.
  • R 4 is H, or halogen.
  • R 4 is H.
  • R 4 is halogen
  • R 4 is C 1 -C 6 alkyl, Cz-Ce alkenyl, or Cz-Ce alkynyl.
  • R 4 is C 1 -C 6 alkyl.
  • R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is propyl. In some embodiments, R 4 is butyl. In some embodiments, R 4 is pentyl. In some embodiments, R 4 is hexyl. In some embodiments, R 4 is isopropyl. In some embodiments, R 4 is isobutyl. In some embodiments, R 4 is isopentyl. In some embodiments, R 4 is isohexyl. In some embodiments, R 4 is secbutyl. In some embodiments, R 4 is secpentyl. In some embodiments, R 4 is sechexyl. In some embodiments, R 4 is tertbutyl.
  • R 4 is methyl
  • R 4 is C 3 -C 12 cycloalkyl.
  • R 5 is C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, Co-Cio aryl, or 5- to 10-membered heteroaryl, wherein the C 3 -C 12 cycloalkyl, 3- to 12- membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R ,a .
  • R 5 is C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the C 3 -C 12 cycloalkyl, 3- to 12- membered heterocycloalkyl, Ce-Cro aryl, or 5- to 10-membered heteroaryl is substituted with one or more R 5a .
  • R 5 is C 3 -C 12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl.
  • R 5 is 3- to 12-membered heterocycloalkyl, or 5- to 10- membered heteroaryl, wherein the 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R 3a
  • R 5 is 3- to 12-membered heterocycloalkyl, or 5- to 10- membered heteroaryl, wherein the 3- to 12-membered heterocycloalkyl, or 5- to 10-membered heteroaryl is substituted with one or more R 5a
  • R’ is 3- to 12-membered heterocycloalkyl, or 5- to 10- membered heteroaryl.
  • R 5 is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R 5a .
  • IV is 3- to 12-membered heterocycloalky] substituted with one or more R 5a .
  • R 5 is 3- to 12-membered heterocycloalkyl.
  • R 5 is a bicyclic 3- to 12-membered heterocycloalkyl.
  • R 5 is a fused 3- to 12-membered heterocycloalkyl.
  • R 5 is a spiro 3- to 12-membered heterocycloalkyl.
  • R 5 is a bridged 3- to 12-membered heterocycloalkyl.
  • R 5 is morpholinyl optionally substituted with one or more R 5a .
  • R 5 is azetidinyl optionally substituted with one or more R Sa .
  • R 5 is pyrrolidinyl optionally substituted with one or more R 3a .
  • R 5 is piperidinyl optionally substituted with one or more R ⁇ a .
  • R 5 is piperazinyl optionally substituted with one or more R- a .
  • R 5 is 2-oxa-7-azaspiro[3.5]nonanyl optionally substituted with one or more R Sa .
  • R 5 is 2-oxa-6-azaspiro[3.5]nonanyl optionally substituted with one or more R 5a .
  • R 5 is morpholinyl substituted with one or more R 5a .
  • R’ is azetidinyl substituted with one or more R’ a .
  • R’ is pyrrolidinyl substituted with one or more R 5a .
  • R 5 is piperidinyl substituted with one or more R 5a .
  • R 5 is piperazinyi substituted with one or more R Sa .
  • R 5 is 2-oxa-7-azaspiro[3.5]nonanyl substituted with one or more R 5a .
  • R’ is 2-oxa-6-azaspiro[3.5]nonanyl substituted with one or more R 5a .
  • R 5 is morpholinyl. In some embodiments, R 5 is azetidinyl. In some embodiments, R 5 is pyrrolidinyl. In some embodiments, R 5 is piperidinyl. In some embodiments, R 5 is piperazinyi. In some embodiments, R' is 2-oxa-7-azaspiro[3.5]nonanyl. In some embodiments, R 5 is 2-oxa-6-azaspiro[3.5]nonanyL
  • R 5 is 5- to 10-membered heteroaryl optionally substituted with one or more R’ a .
  • R 5 is 5- to 10-membered heteroaryl substituted with one or more R 5a .
  • R 5 is 5- to 10-membered heteroaryl.
  • R 5 is pyridinyl
  • each R Sa independently is halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the Ci- C& alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxyl, Ck-Cio aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is halogen.
  • each R 5a independently is halogen.
  • each R ,a independently is F, Cl, Br, or I. In some embodiments, each R 5a independently is F, Cl, or Br. In some embodiments, each R 5a independently is F or Ci.
  • each R 5a independently is F. In some embodiments, each R Sa independently is Cl. In some embodiments, each R 5a independently is Br. In some embodiments, each R 5a independently is I.
  • each R 5a independently is Ci-Ck alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 1 -C 6 alkoxyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C1-C6 alkoxyl is optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 1 -C 6 alkoxyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C1-C6 alkoxyl is substituted with one or more halogen or CI -CG alkyl.
  • each R 5a independently is C 1 -C 6 alkyd, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, or C 1 -C 6 alkoxyl.
  • each R ,a independently is C 1 -C 6 alkyl, or C 1 -C 6 alkoxyl, wherein the CJ -CG alkyl, or C 1 -C 6 alkoxyl is optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is C 1 -C 6 alkyl, or C 1 -C 6 alkoxyl, wherein the C 1 -C 6 alkyl, or C 1 -C 6 alkoxyl is substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is C 1 -C 6 alkyl, or C 1 -C 6 alkoxyl.
  • each R 5a independently is C 1 -C 6 alkyl optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is C 1 -C 6 alkyl substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is C 1 -C 6 alkyl.
  • each R 5a independently is methyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is ethyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is propyl optionally substituted with one or more halogen. In some embodiments, each R ⁇ a independently is butyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is pentyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is hexyl optionally substituted with one or more halogen.
  • each R 5a independently is isopropyl optionally substituted with one or more halogen. In some embodiments, each R’ a independently is isobutyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is isopentyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is isohexyl optionally substituted with one or more halogen. In some embodiments, each R Sa independently is secbutyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is secpentyl optionally substituted with one or more halogen.
  • each R 5a independently is sechexyl optionally substituted with one or more halogen. In some embodiments, each R 5a independently is tertbutyl optionally substituted with one or more halogen. [0180] In some embodiments, each R 5a independently is methyl substituted with one or more halogen. In some embodiments, each R Sa independently is ethyl substituted with one or more halogen. In some embodiments, each R 3a independently is propyl substituted with one or more halogen. In some embodiments, each R 3a independently is butyl substituted with one or more halogen. In some embodiments, each R 5a independently is pentyl substituted with one or more halogen.
  • each R 3a independently is hexyl substituted with one or more halogen. In some embodiments, each R 5a independently is isopropyl substituted with one or more halogen. In some embodiments, each R 5a independently is isobutyl substituted with one or more halogen. In some embodiments, each R 3a independently is isopentyl substituted with one or more halogen. In some embodiments, each R 3a independently is isohexyl substituted with one or more halogen. In some embodiments, each R 3a independently is secbutyl substituted with one or more halogen. In some embodiments, each R 5a independently is secpentyl substituted with one or more halogen. In some embodiments, each R 3a independently is sechexyl substituted with one or more halogen. In some embodiments, each R 5a independently is tertbutyl substituted with one or more halogen.
  • each R 3a independently is methyl. In some embodiments, each R 3a independently is ethyl. In some embodiments, each R 5a independently is propyl. In some embodiments, each R 5a independently is butyl. In some embodiments, each R 5a independently is pentyl. In some embodiments, each R 3a independently is hexyl. In some embodiments, each R 3a independently is isopropyl. In some embodiments, each R 3a independently is isobutyl. In some embodiments, each R 3a independently is isopentyl. In some embodiments, each R 3a independently is isohexyl. In some embodiments, each R 3a independently is secbutyl. In some embodiments, each R 5a independently is secpentyl. In some embodiments, each R 5a independently is sechexyl. In some embodiments, each R 5a independently is tertbutyl.
  • each R 3a independently is C 1 -C 6 alkoxyl optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 3a independently is C 1 -C 6 alkoxy! substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 3a independently is C 1 -C 6 alkoxyl.
  • each R 5a independently i s methoxy. In some embodiments, each R 5a independently is ethoxy. In some embodiments, each R 3a independently is propoxy. In some embodiments, each R 5a independently is butoxy. In some embodiments, each R 5a independently is pentoxy. In some embodiments, each R Sa independently is hexoxy. [0186] In some embodiments, each R 3a independently is CG-CIO and, or 5- to 10-membered heteroaryl, wherein the CG-CW and, or 5- to 10-membered heteroaryl is optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is CG-CIO aryl, or 5- to 10-membered heteroaryl, wherein the CG-CIO aryl, or 5- to 10-membered heteroaryl is substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is CG-CIO aryl, or 5- to 10-membered heteroaryl.
  • each R 5a independently is CG-CSO aryl optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R Sa independently is CG-CW aryl substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is CG-CIO aryl.
  • each R 5a independently is phenyl optionally substituted with one or more halogen.
  • each R 3a independently is phenyl substituted with one or more halogen.
  • each R 5a independently is phenyl.
  • each R 5a independently is 5- to 10-membered heteroaryl optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 3a independently is 5- to 10-membered heteroaryl substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is 5- to 10-membered heteroaryl.
  • each R 33 independently is pyrazolyl optionally substituted with one or more halogen or C 1 -C 6 alkyl.
  • each R 5a independently is pyrazolyl optionally substituted with one or more C 1 -C 6 alkyl.
  • each R 5a independently is pyrazolyl substituted with one or more CJ -CG alkyl.
  • each R 33 independently is pyrazolyl substituted with one or more methyl.
  • each R 5a independently is pyrazolyl.
  • T is -(C 1 -C 6 alkyl)-*, -(C 1 -C 6 alkyl)-()-*, or -(C 1 -C 6 alkyl)- NR 1 -*, wherein * denotes attachment to A.
  • T is -(C 1 -C 6 alkyl)-*, or -(C 1 -C 6 alkyl)-NR r -*, wherein * denotes attachment to A.
  • T is -(C 1 -C 6 alkyl)-*, wherein * denotes attachment to A.
  • T is branched -(C 1 -C 6 alkyl)-*, wherein * denotes attachment to A.
  • T is -CH(CH?)-*, wherein * denotes attachment to A.
  • T is -(C 1 -C 6 alkyl)-O-*, wherein * denotes attachment to A.
  • T is -CH(CH3)-O-*, wherein * denotes attachment to A.
  • T is -(C 1 -C 6 alkyl)-NR T -*, wherein * denotes attachment to A.
  • T is -CH(CH3)-NR 1 -*, wherein * denotes attachment to A.
  • T is -CH(CH3)-NH-*, wherein * denotes attachment to A.
  • each R T is II or C 1 -C 6 alkyl.
  • R ! is H or C1-C6 alkyl.
  • R ! is H.
  • R 1 is C 1 -C 6 alkyl.
  • A is C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C6-C10 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C12 cycloalkyl, 3- to 12- membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R A .
  • A is C3-C12 cycloalkyl, 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the C3-C12 cycloalkyl, 3- to 12- membered. heterocycloalkyl, C6-C10 and, or 5- to 10-membered heteroaryl is substituted with one or more R A .
  • A is 3- to 12-membered heterocycloalkyl, Ce-Cw aryl, or 5- to 10-membered heteroaryl, wherein the 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R A
  • A is 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the 3- to 12-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 10-membered heteroaryl is substituted with one or more R A .
  • A is 3- to 12-membered heterocycloalkyl optionally substituted with one or more R A
  • A is 3- to 12-membered heterocycloalkyl substituted with one or more R A .
  • A is 3- to 12-membered heterocycloalkyl.
  • A is C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the C6-C10 aryl, or 5- to 10-membered heteroaryl is optionally substituted with one or more R A .
  • A is C 6 -C 10 aryl, or 5- to 10-membered heteroaryl, wherein the Co-Cio aryl, or 5- to 10-membered heteroaryl is substituted with one or more R A
  • A is C 6 -C 10 aryl, or 5- to 10-membered heteroaryl.
  • A is C 6 -C 10 aryl optionally substituted with one or more R A .
  • A is C 6 -C 10 and substituted with one or more R A
  • A is C 6 -C 10 aryl.
  • A is phenyl optionally substituted with one or more R A .
  • A is phenyl substituted with one or more R A
  • A is phenyl
  • A is 5- to 10-membered heteroaryl optionally substituted with one or more R A .
  • A is 5- to 10-membered heteroaryl substituted with one or more
  • A is 5- to 10-membered heteroaryl.
  • A is pyridinyl optionally substituted with one or more R A .
  • A is pyridinyl substituted with one or more R A .
  • A is pyridinyl
  • A is 2,3-dihydrobenzo[b]thiophene optionally substituted with one or more R A .
  • A is pyrazolyl optionally substituted with one or more R A .
  • A is pyridinyl optionally substituted with one or more R A .
  • A is [l,2,4]triazolo[4,3-a]pyridinyl optionally substituted with one or more R A .
  • A is thiophenyl optionally substituted with one or more R A
  • A is 2,3-dihydrobenzo[b]thiophene substituted with one or more R A .
  • A is pyrazolyl substituted with one or more R A .
  • A is pyridinyl substituted with one or more R A In some embodiments, A is
  • A is thiophenyl substituted with one or more R A .
  • A is 2,3-dihydrobenzo[b]thiophene. In some embodiments, A is pyrazolyl. In some embodiments, A is pyridinyl. In some embodiments, A is
  • A is thiophenyl.
  • each R A independently is oxo, halogen, -OH, cyano, -NH 2 , - C( 0)011. -Ct O)O(Ci-Cr. alkyl), -C( O) ⁇ (R ' 1 h.
  • each R A independently is oxo, halogen, -OH, cyano, or -NH2.
  • each R A independently is oxo.
  • each R A independently is halogen.
  • each R A independently is F, Cl, Br, or I. In some embodiments, each R A independently is F, Cl, or Br. In some embodiments, each R A independently is F or Ci. [0250] In some embodiments, each R A independently is F. In some embodiments, each R A independently is Cl. In some embodiments, each R A independently is Br. In some embodiments, each R A independently is I.
  • each R A independently is -OH.
  • each R A independently is cyano.
  • each R A independently is -NH2.
  • each R A independently is -C( :::: O)OH.
  • each R A independently is -C( ::: O)O(C 1 -C 6 alkyl), wherein the alkyl is substituted with one or more R A! .
  • each R A independently is -C( : ()) ⁇ )((' i-Ce alkyl).
  • each R A independently is - S( ::: 0)2(ethyl) optionally substituted with one or more R A1 .
  • each R A independently is -S( ::::: 0)2(butyl) optionally substituted with one or more R Ai .
  • each R A independently is - S( :::: O)2(secbutyl) optionally substituted with one or more R Ai .
  • each R A independently is -S( ::::: O)2(sechexyl) optionally substituted with one or more R Ai .
  • each R A independently is C 1 -C 6 alkyl optionally substituted with one or more R Ai .
  • each R A independently is C 1 -C 6 alkyl substituted with one or
  • each R A independently is C 1 -C 6 alkyl.
  • each R A independently is methyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is ethyl optionally substituted with one or more R Ai . In some embodiments, each R A independently is propyl optionally substituted with one or more R Al . In some embodiments, each R A independently is butyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is pentyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is hexyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is isopropyl optionally substituted with one or more R A! .
  • each R A independently is isobutyl optionally substituted with one or more R Ai . In some embodiments, each R A independently is isopentyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is isohexyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is secbutyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is secpentyl optionally substituted with one or more R Ai . In some embodiments, each R A independently is sechexyl optionally substituted with one or more R A1 . In some embodiments, each R A independently is tertbutyl optionally substituted with one or more R A1 .
  • each R A independently is methyl substituted with one or more R Ai . In some embodiments, each R A independently is ethyl substituted with one or more R A! . In some embodiments, each R A independently is propyl substituted with one or more R Ai . In some embodiments, each R A independently is butyl substituted with one or more R A! . In some embodiments, each R A independently is pentyl substituted with one or more R A1 . In some embodiments, each R A independently is hexyl substituted with one or more R A1 . In some embodiments, each R A independently is isopropyl substituted with one or more R. A! .
  • each R A independently is isobutyl substituted with one or more R A! . In some embodiments, each R A independently is isopentyl substituted with one or more R Ai . In some embodiments, each R A independently is isohexyl substituted with one or more R Ai . In some embodiments, each R A independently is secbutyl substituted with one or more R A1 . In some embodiments, each R A independently is secpentyl substituted with one or more R A1 . In some embodiments, each R A independently is sechexyl substituted with one or more R A1 . In some embodiments, each R A independently is tertbutyl substituted with one or more R A1 .
  • each R A independently is methyl. In some embodiments, each R A independently is ethyl. In some embodiments, each R A independently is propyl. In some embodiments, each R A independently is butyl. In some embodiments, each R A independently is pentyl. In some embodiments, each R A independently is hexyl. In some embodiments, each R A independently is isopropyl. In some embodiments, each R A independently is isobutyl. In some embodiments, each R A independently is isopentyl. In some embodiments, each R A independently is isohexyl. In some embodiments, each R A independently is secbutyl. In some embodiments, each R A independently is secpentyl.
  • alkynyl, C 1 -C 6 alkoxyl, or Cz-Ciz cycloalkyl wherein the Cz-Ciz cycloalkyl is optionally substituted with - OH, or two R A1 , together with the atoms they are attached, form a 3- to 12-membered heterocycloalkyl or C 3 -C 12 cycloalkyl, wherein the 3- to 12-membered heterocycloalkyl or C3- C12 cycloalkyl is optionally substituted with one or more oxo, halogen, cyano, -OH, or -NT I 2.
  • two R A1 together with the atoms they are attached, form a 3- to 12-membered heterocycloalkyl or C 3 -C 12 cycloalky], wherein the 3- to 12-membered heterocycloalkyl or C 3 -C 12 cycloalkyl is optionally substituted with one or more oxo, halogen, cyano, -OH, or -NH2.
  • each R A! independently is H, halogen, -OH, or -NHz.
  • each R A1 independently is H.
  • each R A1 independently is halogen.
  • each R A1 independently is F, Cl, Br, or I. In some embodiments, each R A1 independently is F, Cl, or Br. In some embodiments, each R A1 independently is F or Cl.
  • each R A1 independently is F. In some embodiments, each R A1 independently is Cl. In some embodiments, each R A1 independently is Br. In some embodiments, each R A1 independently is I.
  • each R A1 independently is -OH.
  • each R A1 independently is -NH2.
  • each R A! independently is C 3 -C 12 cycloalky] optionally substituted with -OH.
  • each R A1 independently is C 3 -C 12 cycloalkyl substituted with - OH.
  • each R A1 independently is C 3 -C 12 cycloalkyl.
  • the compound is of Formula ( I -a ): or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is of Formula (I-b): or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is of Formula (I-c): or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is of Formula (I-d):
  • the compound is of Formula ( I -e ): or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is of Formula (I-f): or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is of Formula (I-g), (I-h), -i), (I-j), (I-k), or (I- 1):
  • the compound is of Formula (I-m): or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is of Formula (I-n): or a pharmaceutically acceptable salt or stereoisomer thereof.
  • the compound is a compound described in Table 1 or Table 2, or a prodrug or pharmaceutically acceptable salt thereof.
  • the compound is a compound described in Table 1 or Table 2, or a pharmaceutically acceptable salt thereof.
  • the compound is a prodrug of a compound described in Table 1 or Table 2, or a pharmaceutically acceptable salt thereof.
  • the compound is a compound described in Table 1 or Table 2. [0305] In some embodiments, the compound is a compound described in Table 1, or a prodrug or pharmaceutically acceptable salt thereof.
  • the compound is a compound described in Table 1, or a pharmaceutically acceptable salt thereof.
  • the compound is a prodrug of a compound described in Table
  • the compound is a compound described in Table I .
  • the compound is a compound described in Table 2, or a prodrug or pharmaceutically acceptable salt thereof.
  • the compound is a compound described in Table 2, or a pharmaceutically acceptable salt thereof.
  • the compound is a prodrug of a compound described in Table
  • the compound is a compound described in Table 2.
  • the compound is a pharmaceutically acceptable salt of a compound described in Table I .
  • the compound is a pharmaceutically acceptable salt of a compound described in Table 2.
  • the present disclosure provides a compound being an isotopic derivative (e.g., isotopically labeled compound) of any one of the compounds of the Formulae disclosed herein.
  • the compound is an isotopic derivative of any one of the compounds described in Table 1, or a prodrug or pharmaceutically acceptable salt thereof.
  • the compound is an isotopic derivative of any one of the compounds described in Table 1 or a pharmaceutically acceptable salt thereof.
  • the compound is an isotopic derivative of any one of prodrags of the compounds described in Table 1 or a pharmaceutically acceptable salt thereof.
  • the compound is an isotopic derivative of any one of the compounds described in Table 1.
  • the compound is an isotopic derivative of any one of the compounds described in Table 2, or a prodrug or pharmaceutically acceptable salt thereof.
  • the compound is an isotopic derivative of any one of the compounds described in Table 2 or a pharmaceutically acceptable salt thereof.
  • the compound is an isotopic derivative of any one of prodrugs of the compounds described in Table 2 or a pharmaceutically acceptable salt thereof.
  • the compound is an isotopic derivative of any one of the compounds described in Table 2.
  • the isotopic derivative can be prepared using any of a variety of art-recognised techniques.
  • the isotopic derivative can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
  • the isotopic derivative is a deuterium labeled compound.
  • the isotopic derivative is a deuterium labeled compound of any one of the compounds of the Formulae disclosed herein.
  • isotopic derivative refers to a derivative of a compound in which one or more atoms are isotopically enriched or labelled.
  • an isotopic derivative of a compound of Formula (I) is isotopically enriched with regard to, or labelled with, one or more isotopes as compared to the corresponding compound of Formula (I).
  • the isotopic derivative is enriched with regard to, or labelled with, one or more atoms selected from 2 H, i3 C, i4 C, i 5 N, !8 O, 29 Si, 31 P, and 34 S.
  • the isotopic derivative is a deuterium labeled compound (i.e., being enriched with 2 H with regard to one or more atoms thereof).
  • the compound is a 18 F labeled compound.
  • the compound is a 123 I labeled compound, a !24 I labeled compound, a ! 25 I labeled compound, a 129 I labeled compound, a f 3i I labeled compound, a !3 ’I labeled compound, or any combination thereof.
  • the compound is a 33 S labeled compound, a 34 S labeled compound, a 3, S labeled compound, a "’S labeled compound, or any combination thereof.
  • the 18 F, 133 1, 32 S, 34 S, s5 S, and/or 56 S labeled compound can be prepared using any of a variety of art-recognised techniques.
  • the deuterium labeled compound can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples described herein, by substituting a iS F, i23 I, 124 I, i25 1, 129 1, 131 1, 135 1, 3 S, 34 S, 3:, S, and/or 3b S labeled reagent for a non-isotope labeled reagent.
  • a compound of the invention or a pharmaceutically acceptable salt or solvate thereof that contains one or more of the aforementioned 18 F, 123 I, lz4 I, 125 I, 129 I, 131 I, 13: 'I, ' 2 S, ' 4 S, 35 S, and 3b S atom(s) is within the scope of the invention.
  • substitution with isotope e.g, 18 F, l23 I, 124 I, 125 I, i2y I, 13i I, 133 I, 3 S, 34 S, 33 S, and/or 36 S
  • the various functional groups and substituents making up the compounds of the Formula (I) are typically chosen such that the molecular weight of the compound does not exceed 1000 daltons. More usually, the molecular weight of the compound will be less than 900, for example less than 800, or less than 750, or less than 700, or less than 650 daltons. In some embodiments, the molecular weight is less than 600 and, for example, is 550 daltons or less.
  • a suitable pharmaceutically acceptable salt of a compound of the disclosure is, for example, an acid-addition salt of a compound of the disclosure which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid.
  • an inorganic organic acid for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid.
  • a suitable pharmaceutically acceptable salt of a compound of the disclosure which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or t.ris-(2-hydroxyethyl)amine.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium or magnesium salt
  • an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine or t.ris-(2-hydroxyethyl)amine.
  • the term “isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture.”
  • chiral centre refers to a carbon atom bonded to four n oni den ti cal sub stituent s .
  • chiral isomer means a compound with at least one chiral centre.
  • Compounds with more than one chiral centre may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture.”
  • a stereoisomer may be characterised by the absolute configuration (R or S) of that chiral centre.
  • Absolute configuration refers to the arrangement in space of the substituents attached to the chiral centre.
  • the substituents attached to the chiral centre under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit.
  • geometric isomer means the diastereomers that owe their existence to hindered rotation about double bonds or a cycloalkyl linker (e.g., 1,3-cyclobutyl). These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
  • atropic isomers are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques, it has been possible to separate mixtures of two atropic isomers in select cases.
  • tautomer is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solutions where tautomerisation is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible by tautomerisations is called tautomerism. Of the various types of tautomerism that are possible, two are commonly observed.
  • keto-enol tautomerism a simultaneous shift of electrons and a hydrogen atom occurs.
  • Ring-chain tautomerism arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
  • An enantiomer can be characterised by the absolute configuration of its asymmetric centre and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarised light and designated as dextrorotatory' or levorotatory’ (i.e., as (+) or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.
  • the compounds of this disclosure may possess one or more asymmetric centres; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof.
  • the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of “Advanced Organic Chemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form.
  • Some of the compounds of the disclosure may have geometric isomeric centres (E- and Z ⁇ isomers). It is to be understood that the present disclosure encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that modulate PI3Ka activity.
  • the present disclosure also encompasses compounds of the disclosure as defined herein which comprise one or more isotopic substitutions.
  • any Formula described herein include the compounds themselves, as well as their salts, and their solvates, if applicable.
  • a salt for example, can be formed between an anion and a positively charged group (e.g., amino) on a substituted compound disclosed herein.
  • Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).
  • the term “pharmaceutically acceptable anion” refers to an anion suitable for forming a pharmaceutically acceptable salt.
  • a salt can also be formed between a cation and a negatively charged group (e.g., carboxylate) on a substituted compound disclosed herein.
  • Suitable cations include sodium ion, potassium ion, magnesium ion, calcium ion, and an ammonium cation such as tetramethylammonium ion or diethylamine ion.
  • the substituted compounds disclosed herein also include those salts containing quaternary nitrogen atoms.
  • the compounds of the present disclosure can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
  • Nonlimiting examples of hydrates include monohydrates, dihydrates, etc.
  • Nonlimiting examples of solvates include ethanol solvates, acetone solvates, etc.
  • solvate means solvent addition forms that contain either stoichiometric or non-stoichiometric amounts of solvent. Some compounds have a tendency to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water the solvate formed is a hydrate; and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more molecules of water with one molecule of the substance in which the water retains its molecular state as H2O.
  • analog refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group, or the replacement of one functional group by another functional group).
  • an analog is a compound that is similar or comparable in function and appearance, but not in structure origin to the reference compound.
  • derivative refers to compounds that have a common core structure and are substituted with various groups as described herein.
  • bioisostere refers to a compound resulting from the exchange of an atom or of a group of atoms with another, broadly similar, atom or group of atoms.
  • the objective of a bioisosteric replacement is to create a new compound with similar biological properties to the parent compound.
  • the bioisosteric replacement may be physicochemically or topologically based.
  • Examples of carboxylic acid bioisosteres include, but are not limited to, acyl sulfonamides, tetrazoles, sulfonates and phosphonates. See, e.g., Patani and LaVoie, Chem. Rev. 96, 3147-3176, 1996.
  • solvated forms such as, for example, hydrated forms.
  • a suitable pharmaceutically acceptable solvate is, for example, a hydrate such as hemi-hydrate, a mono-hydrate, a di-hydrate or a tri-hydrate. It is to be understood that the disclosure encompasses all such solvated forms that modulate PI3Ka activity.
  • N-oxides Compounds of any one of the Formulae disclosed herein containing an amine function may also form N-oxides.
  • a reference herein to a compound of Formula (I) that contains an amine function also includes the N-oxide.
  • one or more than one nitrogen atom may be oxidised to form an N-oxide.
  • Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogencontaining heterocycle.
  • N-oxides can be formed by treatment of the corresponding amine with an oxidising agent such as hydrogen peroxide or a peracid (e.g.
  • N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with meta-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.
  • mCPBA meta-chloroperoxybenzoic acid
  • the compounds of any one of the Formulae disclosed herein may be administered in the form of a prodrug which is broken down in the human or animal body to release a compound of the disclosure.
  • a prodrug may be used to alter the physical properties and/or the pharmacokinetic properties of a compound of the disclosure.
  • a prodrug can be formed when the compound of the disclosure contains a suitable group or substituent to which a propertymodifying group can be attached. Examples of prodrugs include derivatives containing in vivo cleavable alkyl or acyl substituents at the ester or amide group in any one of the Formulae disclosed herein.
  • the present disclosure includes those compounds of any one of the Formulae disclosed herein as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a prodrag thereof. Accordingly, the present disclosure includes those compounds of any one of the Formulae disclosed herein that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of any one of the Formulae disclosed herein may be a synthetically-produced compound or a metabolically-produced compound.
  • a suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein is one that is based on reasonable medical judgment as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.
  • Various forms of prodrug have been described, for example in the following documents: a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H.
  • Bundgaard Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 1 13-191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988), f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery' Systems”, A.C.S. Symposium Series, Volume 14; and h) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.
  • a suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof.
  • An in vivo cleavable ester or ether of a compound of any one of the Formulae disclosed herein containing a hydroxy group is, for example, a pharmaceutically acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound.
  • Suitable pharmaceutically acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters).
  • ester forming groups for a hydroxy group include Ci-Cw alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, Ci-Cio alkoxycarbonyl groups such as ethoxycarbonyl, N,N-(CI-C6 alkyl)?.carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
  • Ci-Cw alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups
  • Ci-Cio alkoxycarbonyl groups such as ethoxycarbonyl, N,N-(CI-C6 alkyl)?.carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
  • Suitable pharmaceutically acceptable ether forming groups for a hydroxy group include a-acyloxyalkyl groups such as acetoxymethyl and pi val oy 1 oxy m ethyl group s .
  • a suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a Ci-4alkylamine such as methylamine, a (C1-C4 alkylljamine such as dimethylamine, N-ethyl-N-methylamine or diethylamine, a C1-C4 alkoxy-C2-C4 alkylamine such as 2-methoxy ethyl amine, a phenyl-Ci- C4 alkylamine such as benzylamine and amino acids such as glycine or an ester thereof.
  • an amine such as ammonia
  • a Ci-4alkylamine such as methylamine
  • a (C1-C4 alkylljamine such as dimethylamine, N-ethyl-N-methylamine or diethylamine
  • a suitable pharmaceutically acceptable prodrug of a compound of any one of the Formulae disclosed herein that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof.
  • Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C1-C10 alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups.
  • ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N- dialkylaminomethyl,morpholinomethyl,piperazin-l-ylmethyl and 4-(CI-C4 alkyl)piperazin-l- ylmethyl .
  • the in vivo effects of a compound of any one of the Formulae disclosed herein may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of any one of the Formulae disclosed herein. As stated hereinbefore, the in vivo effects of a compound of any one of the Formulae disclosed herein may also be exerted by way of metabolism of a precursor compound (a prodrug).
  • the present disclosure excludes any individual compounds not possessing the biological activity defined herein.
  • the present disclosure provides a method of preparing a compound of the present disclosure.
  • the present disclosure provides a method of a compound, comprising one or more steps as described herein.
  • the present disclosure provides a compound obtainable by, or obtained by, or directly obtained by a method for preparing a compound as described herein.
  • the present disclosure provides an intermediate as described herein, being suitable for use in a method for preparing a compound as described herein.
  • the compounds of the present disclosure can be prepared by any suitable technique known in the art. Particular processes for the preparation of these compounds are described further in the accompanying examples.
  • a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxy carbonyl group, for example a methoxycarbonyl, ethoxycarbonyl, or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyl oxy carbonyl, or an aroyl group, for example benzoyl.
  • the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed by, for example, hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
  • an acyl group such as a tert-butoxy carbonyl group may be removed, for example, by treatment, with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyl oxy carbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon, or by treatment with a Lewis acid for example boron tri s(tri fluoroacetate).
  • a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hy drazine.
  • a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
  • the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
  • an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia.
  • a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia.
  • an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
  • a suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
  • a base such as sodium hydroxide
  • a tert-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon.
  • the processes may then further comprise the additional steps of (i) removing any protecting groups present; (ii) converting the compound Formula (I) into another compound of Formula (I); (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and/or (iv) forming a prodrug thereof.
  • the reaction of the compounds is carried out in the presence of a suitable solvent, which is preferably inert under the respective reaction conditions.
  • suitable solvents comprise but are not limited to hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene, chlorinated hydrocarbons, such as trichlorethylene, 1,2- dichloroethane, tetrachloromethane, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran ( 1 HF), 2-methyltetrahydrofuran, cyclopentylmethyl ether (CPME), methyl tert-butyl ether (MTBE) or dioxane; glycol ethers
  • Reaction times are generally in the range between a fraction of a minute and several days, depending on the reactivity of the respective compounds and the respective reaction conditions. Suitable reaction times are readily determinable by methods known in the art, for example reaction monitoring. Based on the reaction temperatures given above, suitable reaction times generally lie in the range between 10 minutes and 48 hours.
  • some of the compounds of the present disclosure can readily be synthesised by reacting other compounds of the present disclosure under suitable conditions, for instance, by converting one particular functional group being present in a compound of the present disclosure, or a suitable precursor molecule thereof, into another one by applying standard synthetic methods, like reduction, oxidation, addition or substitution reactions; those methods are well known to the skilled person.
  • the skilled person will apply - whenever necessary or useful - synthetic protecting (or protective) groups; suitable protecting groups as well as methods for introducing and removing them are well- known to the person skilled in the art of chemical synthesis and are described, in more detail, in, e.g., P.G.M. Wuts, T.W. Greene, “Greene’s Protective Groups in Organic Synthesis”, 4th edition (2006) (John Wiley & Sons).
  • the indoline dione (1) can be halogenated to afford appropriately substituted dione (2).
  • Condensation between dione (2) and maleic acid gives ring expanded quinoline carboxylic acid (3).
  • Treatment of quinoline (3) with phosphorus oxychloride may afford acyl chloride (4) which can be converted to primary amide (5).
  • Hydrolysis of amide (5) to nitrile (6) under acid conditions can be followed with substitution reactions with a variety of amines to effect formation of quinolines (7).
  • Palladium-catalyzed acylation of halide (7) may give acyl quinoline (8).
  • racemates (8) can then be purified on a chiral column to give arbitrarily assigned pure enantiomers (1 1) and (12) .
  • ketone (8) can be reduced to alcohol (9) with a reducing agent such as sodium borohydride. This alcohol (9) can then be converted to aryl amine (10) in the presence of copper bromide. Racemic amine (10) can then be purified on a chiral column to give arbitrarily assigned pure enantiomers (11) and (12).
  • a reducing agent such as sodium borohydride.
  • This alcohol (9) can then be converted to aryl amine (10) in the presence of copper bromide. Racemic amine (10) can then be purified on a chiral column to give arbitrarily assigned pure enantiomers (11) and (12).
  • Compounds designed, selected and/or optimised by methods described above, once produced, can be characterised using a variety of assays known to those skilled in the art to determine whether the compounds have biological activity.
  • the molecules can be characterised by conventional assays, including but not limited to those assays described below, to determine whether they have a predicted activity, binding activity and/or binding specificity.
  • high-throughput, screening can be used to speed up analysis using such assays.
  • it can be possible to rapidly screen the molecules described herein for activity, using techniques known in the art.
  • General methodologies for performing high- throughput screening are described, for example, in Devlin (1998) High Throughput Screening, Marcel Dekker; and U.S. Patent No. 5,763,263.
  • High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.
  • in vitro or in vivo biological assays are may be suitable for detecting the effect of the compounds of the present disclosure.
  • These in vitro or in vivo biological assays can include, but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, in vitro cell viability assays, and the assays described herein.
  • the biological assay is described in the Examples herein.
  • the biological acti vity of the compounds may be determined utilizing a p-AKT S473 assay.
  • cells e.g., MCF10A-PI3Ka-WT, MCF10A- PI3Ka-H1047R and MCF10A- PI3Ka-E545K cells
  • cells may be dissociated with TryPLE, washed with media and plated in wells plate.
  • serial dilution of compounds were applied to the cell.
  • p-AKT S473 may be measured using HTRF cellular kit by Cisbio (64.AKSPET) according to manufacturer’s protocol. In some embodiments, p-AKT S473 levels may be measured using the kit.
  • the cells e.g., MCF10A-PI3Ka-WT, MCF10A- PI3Ka-H1047R and MCF10A- PI3Ka-E545K cells
  • the cells may be lysed.
  • antibodies may be mixed with detection buffer and may be added to the lysate and may be incubated overnight.
  • luminescence may be read on a plate reader (e.g., Ensight plate reader).
  • luminescence may be read at 665 nm. In some embodiments, luminescence may be read at 620 nm wavelengths. In some embodiments, a decrease in p-AKT S473 levels indicate a downregulation of the PI3Ka pathway. In some embodiments, a decrease in p-AKT S473 levels indicate a downregulation of cell proliferation.
  • the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure as an active ingredient.
  • the present disclosure provides a pharmaceutical composition comprising at least one compound of each of the formulae described herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • the present disclosure provides a pharmaceutical composition comprising at least one compound selected from Table 1.
  • the present disclosure provides a pharmaceutical composition comprising at least one compound selected from Table 2.
  • composition is intended to encompass a product compri sing the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • the compounds of present disclosure can be formulated for oral administration in forms such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions.
  • the compounds of present disclosure on can also be formulated for intravenous (bolus or in- fusion), intraperitoneal, topical, subcutaneous, intramuscular or transdermal (e.g., patch) administration, all using forms well known to those of ordinary skill in the pharmaceutical arts.
  • the formulation of the present disclosure may be in the form of an aqueous solution comprising an aqueous vehicle.
  • the aqueous vehicle component may comprise water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from the group consisting of a solubility enhancing agent, chelating agent, preservative, tonicity agent, viscosity/suspending agent, buffer, and pH modifying agent, and a mixture thereof.
  • any suitable solubility enhancing agent can be used.
  • a solubility enhancing agent include cyclodextrin, such as those selected from the group consisting of hydroxypropyl-P-cyclodextrin, methyl -p-cyclodextrin, randomly methylated-P-cyclodextrin, ethylated-p-cyclodextrin, triacetyl-p-cyclodextrin, peracetylated-p-cyclodextrin, carboxymethyl-P-cyclodextrin, hydroxy ethyl -P-cyclodextrin, 2-hydroxy-3-
  • Any suitable chelating agent can be used.
  • a suitable chelating agent include those selected from the group consisting of ethylenediaminetetraacetic acid and metal salts thereof disodium edetate, trisodium edetate, and tetrasodium edetate, and mixtures thereof
  • any suitable preservative can be used.
  • a preservative include those selected from the group consisting of quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chi orhexi dine gluconate, benzethonium chloride, cetyl pyridinium chloride, benzyl bromide, phenylmercury nitrate, phenylmercury acetate, phenylmercury neodecanoate, merthiolate, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p-hydroxybenzoate, propyl aminopropyl biguanide, and butyl-p-hydroxybenzoate, and sorbic acid, and mixtures thereof.
  • quaternary ammonium salts such as benzalkonium halides (preferably benzalkonium chloride), chi
  • the aqueous vehicle may also include a tonicity agent to adjust the tonicity (osmotic pressure).
  • the tonicity agent can be selected from the group consisting of a glycol (such as propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and sodium chloride, and a mixture thereof.
  • the aqueous vehicle may also contain a viscosity/suspending agent.
  • Suitable viscosity/suspending agents include those selected from the group consisting of cellulose derivatives, such as methyl cellulose, ethyl cellulose, hydroxyethylcellulose, polyethylene glycols (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethyl cellulose, hydroxypropylmethyl cellulose, and cross-linked acrylic acid polymers (carbomers), such as polymers of acrylic acid cross-linked with polyalkenyl ethers or di vinyl glycol (Carbopol s - such as Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974 and Carbopol 974P), and a mixture thereof.
  • cellulose derivatives such as methyl cellulose, ethyl cellulose, hydroxyethylcellulose
  • polyethylene glycols such as polyethylene glycol 300, polyethylene glycol 400
  • carboxymethyl cellulose such as polyethylene glycol 300, polyethylene glycol 400
  • carboxymethyl cellulose such as polyethylene
  • the formulation may contain a pH modifying agent.
  • the pH modifying agent is typically a mineral acid or metal hydroxide base, selected from the group of potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof and preferably sodium hydroxide and/or hydrochloric acid.
  • the aqueous vehicle may also contain a buffering agent to stabilise the pH.
  • the buffer is selected from the group consisting of a phosphate buffer (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), a borate buffer (such as boric acid, or salts thereof including disodium tetraborate), a citrate buffer (such as citric acid, or salts thereof including sodium citrate), and s-aminocaproic acid, and mixtures thereof
  • the formulation may further comprise a wetting agent.
  • wetting agents include those selected from the group consisting of polyoxypropylene-polyoxyethylene block copolymers (poloxamers), polyethoxylated ethers of castor oils, polyoxyethylenated sorbitan esters (polysorbates), polymers of oxyethylated octyl phenol (Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid glyceryl esters, sucrose fatty esters, and polyoxyethylene fatty esters, and mixtures thereof.
  • Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable earner. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch, a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavouring agent such as peppermint, methyl salicylate, orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch, a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • a sweetening agent such
  • a pharmaceutical composition which comprises a compound of the disclosure as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.
  • compositions of the disclosure may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).
  • oral use for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or
  • compositions of the disclosure may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
  • compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.
  • An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat or prevent a PI3Ku related condition referred to herein, slow 7 its progression and/or reduce the symptoms associated with the condition.
  • An effective amount of a compound of the present disclosure for use in therapy is an amount sufficient to treat a PI3Ka related condition referred to herein, slow' its progression and/or reduce the symptoms associated with the condition.
  • the size of the dose for therapeutic or prophylactic purposes of a compound of Formula (I) will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine. Methods of Use
  • Phosphatidylinositol 3-Kinases are a group of plasma membrane-associated lipid kinases that upon activation catalyze the transfer of phosphate to the D-3’ position of inositol of phosphoinositol-4,5-phosphate (PIP2) to produce phosphoinositol-3,4,5-phosphate (PIP3).
  • PIP3 is a second messenger that binds and recruits a subset of Pleckstrin-homology, FYVE, Phox, or other lipid-binding domains of downstream target to the cell membrane.
  • Signaling proteins e.g.
  • AKT, PDK1 can then bind to the lipid product of PI3K, localize to cell membrane and activate downstream cellular activity that includes transcription, translation, proliferation, survival, chemotaxis, motility, cellular trafficking and metabolism.
  • PI3Ks include a conserved family of 15 kinases that exhibit distinct substrate specificities, expression paterns and modes of regulation. PI3Ks are divided into three classes (I, II and III) based on their structures and substrate specificities.
  • Class I PI3Ks encompass PI3Ks containing one of the pl 10a, p 11 Op, pl 108 and pl 10y catalytic subunits, which are encoded by the PIK3CA, PIK3CB, PIK3CD and PIK3CG genes, respectively. These catalytic subunits are constitutively associated with regulatory subunits: p85a, p55a, p5()a, p85p, p55y, pl 01 or p84.
  • mutations in the gene PJK3CA which encodes the pl 10a (also referred to as PI3Ka) catalytic subunit, have been linked to numerous cancers, including bladder cancer, brain cancer, breast cancer, colon cancer, endometrial cancer, ovarian cancer, skin cancer, stomach cancer, lung cancer and prostate cancer.
  • Mutations in the PIK3CA gene are notably observed within several “mutation hotspots” that are located within the kinase and helicase domains. These mutations include the E542K mutation, the E545K mutation and the H1047R mutation. Moreover, many of these mutations have been shown to be oncogenic gain- of-function mutations.
  • PI3Ks Given the connection to various disease, including cancer, PI3Ks, and more specifically, PI3Ka, have been a target for therapeutic intervention. To this end, multiple inhibitors of PI3Ks have been developed, including alpelisib, buparlisib, taselisib, and inavolisib. These inhibitors are active against one or multiple Class I PI3K isoforms.
  • the present disclosure provides a method of modulating PI3Ka activity (e.g., in vitro or in vivo ⁇ , comprising contacting a cell with an effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of modulating PI3Ka activity (e.g., in vitro or in vivo), comprising contacting a cell with a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of modulating PI3Ka activity (e.g., in vitro or in vivo), comprising contacting a cell with an effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of modulating PI3Ka activity (e.g., in vitro or in vivo), comprising contacting a cell with a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the present disclosure provides a method of treating or preventing a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a compound of the present disclosure or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating a disease or disorder disclosed herein in a subject in need thereof, comprising administering to the subject a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the disease or disorder is associated with an implicated PI3Ka activity. In some embodiments, the disease or disorder is a disease or disorder in which PI3Ka activity is implicated.
  • the disease or disorder is associated with an implicated PI3Ka activity. In some embodiments, the disease or disorder is a disease or disorder in which PI3Ka activity is implicated.
  • the disease or disorder is congenital lipomatous overgrowth, vascular malformations, epidermal naevi, scoliosis/skeletal and spinal (CLOVES) syndrome.
  • the disease or disorder is PIK3CA-related overgrowth svndrome.
  • the disease or disorder is cancer.
  • the cancer is characterized by an amplification (i.e. increase) in the expression of the P1K3CA gene and/or an amplification (he. increase) in the expression of the PI3Ka protein.
  • the cancer is characterized by a decrease in the expression of the PIK3 CA gene and/or decrease in the expression of the PI3Ka protein.
  • the cancer is characterized by at least one oncogenic mutation in the PJK3CA gene. It is understood that a cancer that is characterized by at least one oncogenic mutation in the PIK3CA gene is a cancer that is typically associated with at least one oncogenic mutation in the P1K3CA gene, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic mutation in the PIK3CA gene.
  • the cancer is characterized by at least one oncogenic variant of the PI3Ka protein.
  • a cancer that is characterized by least one oncogenic variant of the PI3Ka protein is a cancer that is typically associated with at least one oncogenic variant of the PI3Ka protein, including, but not limited to, cancers whose primary oncogenic activity is thought to be driven by the at least one oncogenic variant, of the PI3Ka protein.
  • an oncogenic variant of PI3Ka protein is a PI3Ka protein molecule that comprises at. least one oncogenic mutation and that is produced as the result of the expression of a PIK3CA gene that comprises at least one oncogenic mutation.
  • the subject has at least one oncogenic mutation in the PIK3CA [0440] In some embodiments, the subject has at least one tumor and/or cancerous cell that expresses an oncogenic variant of the PI3Ka protein,
  • an oncogenic mutation can include, but is not limited to a mutation that results in the substitution of one amino acid for another at a specific position within the protein product of the gene, a mutation that results in the substitution of one or more amino acids for one or more amino acids between two specific positions within the protein product of the gene, a mutation that results in an insertion of one or more amino acids between two positions within the protein product of the gene, a mutation that results in the deletion of one more amino acids between two positions within the protein product of the gene, and mutation that results in a fusion of the protein product of the gene, or portion thereof, with another protein, or portion thereof, or any combination thereof.
  • an oncogenic mutation can include, but is not limited to, a missense mutation, a nonsynonymous mutation, an insertion of one or more nucleotides, a deletion of one or more nucleotides, an inversion and a deletion-insertion.
  • the gene in the context of a gene (e.g. PIK3CA), can have one or more of the aforementioned types of oncogenic mutations, including combinations of different types of oncogenic mutations.
  • an oncogenic mutation can include, but is not limited to, the substitution of one amino acid for another at a specific position within the protein, the substitution of one or more amino acids for one or more amino acids between two specific positions within the protein, an insertion of one or more amino acids between two positions within the protein, a deletion of one more amino acids between two positions within the protein, and a fusion of the protein, or portion thereof, with another protein, or portion thereof, or any combination thereof.
  • the protein in the context of a protein (e.g. the PI3Ka protein), the protein can have one or more of the aforementioned types of oncogenic mutations, including combinations of different types of oncogenic mutations.
  • an oncogenic mutation of the PI3Ka protein can be any one of E542K, E545K and H1047R (numbering corresponding to SEQ ID NO: 1).
  • a wild-type PI3Ka protein sequence of the present disclosure may comprise, consist essentially of, or consist of the amino acid sequence of: 10 b l WTTKMDW I FH T IKQHALN (SEQ ID NO: 1)
  • the cancer is a carcinoma, a lymphoma, a blastoma, a sarcoma, a leukemia, a brain cancer, a breast cancer, a blood cancer, a bone cancer, a lung cancer, a skin cancer, a liver cancer, an ovarian cancer, a bladder cancer, a renal cancer, a kidney cancer, a gastric cancer, a thyroid cancer, a pancreatic cancer, an esophageal cancer, a prostate cancer, a cervical cancer, a uterine cancer, a stomach cancer, a soft tissue cancer, a laryngeal cancer, a small intestine cancer, a testicular cancer, an anal cancer, a vulvar cancer, a joint cancer, an oral cancer, a pharynx cancer or a colorectal cancer.
  • the cancer is adrenocortical carcinoma, bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma, endocervieal adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, esophageal carcinoma, glioblastoma multiforme, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, acute myeloid leukemia, brain lower grade glioma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, ph eochrom ocy toma, paragangl i om a, prosta
  • cancers include breast cancer, lung cancer, lymphoma, melanoma, liver cancer, colorectal cancer, ovarian cancer, bladder cancer, renal cancer or gastric cancer.
  • Further examples of cancer include neuroendocrine cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, thyroid cancer, endometrial cancer, biliary cancer, esophageal cancer, anal cancer, salivary, cancer, vulvar cancer, cervical cancer, Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Adrenal gland tumors, Anal cancer, Bile duct cancer, Bladder cancer.
  • CUP cancer of unknown primary
  • CLL Chronic lymphocytic leukemia
  • CML Chrome myeloid leukemia
  • Colorectal cancer Ear cancer, Endometrial cancer, Eye cancer, Follicular dendritic cell sarcoma, Gallbladder cancer, Gastric cancer, Gastro
  • Liver cancer Lung cancer, Lymphoma, Malignant, schwannoma, Mediastinal germ cell tumors. Melanoma skin cancer. Men's cancer. Merkel cell skin cancer, Mesothelioma, Molar pregnancy, Mouth and oropharyngeal cancer. Myeloma, Nasal and paranasal sinus cancer, Nasophaiyngeal cancer, Neuroblastoma, Neuroendocrine tumors, Non -Hodgkin lymphoma (NHL), Esophageal cancer, Ovarian cancer, Pancreatic cancer. Penile cancer.
  • Retinoblastoma Salivary gland cancer. Secondary ’ cancer, Signet cell cancer, Skin cancer, Small bowel cancer, Soft tissue sarcoma, Stomach cancer, T cell childhood non Hodgkin lymphoma (NHL), Testicular cancer. Thymus gland cancer. Thyroid cancer. Tongue cancer, Tonsil cancer, Tumors of the adrenal gland, Uterine cancer. Vaginal cancer. Vulval cancer, Wilms' tumor, Womb cancer and Gynaecological cancer. Examples of cancer also include, but are not limited to.
  • Lymphoma Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, Multiple myeloma.
  • Chrome lymphocytic leukemia chronic myeloid leukemia, acute myeloid leukemia, Myelodysplastic syndromes.
  • Myelofibrosis Biliary tract cancer, Hepatocellular cancer. Colorectal cancer. Breast cancer, Lung cancer, Non-small cell lung cancer.
  • the cancer is B-cell lymphoma, adrenocortical carcinoma, bladder urothelial carcinoma, breast cancer, cervical adenocarcinoma, cervical squamous-cell carcinoma, cholangiocarcinoma, colorectal adenocarcinoma, colorectal cancer, diffuse glioma, esophageal squamous-cell cancer, esophagogastric adenocarcinoma, esophagogastric cancer, fibrolamellar carcinoma, germ-cell carcinoma, glioblastoma, glioma, head and neck squamouscell carcinoma, hepatocellular carcinoma, leukemia,
  • the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the present disclosure provides a method of treating cancer in a subj ect in need thereof comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the present disclosure provides a method of treating or preventing cancer in a subject in need thereof, comprising administering to the subject a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the present disclosure provides a method of treating cancer in a subj ect in need thereof, comprising administering to the subject a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in modulating PI3Ka activity (e.g., in vitro or in vivo).
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in modulating PI3Ka activity (e.g., in vitro or in vivo).
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing a disease or disorder disclosed herein.
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating a disease or disorder disclosed herein.
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating or preventing cancer in a subj ect in need thereof.
  • the present disclosure provides a compound of the present disclosure or a pharmaceutically acceptable salt thereof for use in treating cancer in a subject in need thereof.
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for modulating PI3Ka activity (e.g., in vitro or in vivo).
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a disease or disorder disclosed herein.
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or disorder disclosed herein,
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing cancer in a subject in need thereof.
  • the present disclosure provides use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a subject in need thereof.
  • the present disclosure provides compounds that function as modulators of PI3Ka activity.
  • the compounds of the present di sclosure are inhibitors of the PI3Ka protein. In some embodiments, the compounds of the present disclosure specifically inhibit mutated PI3 Ka protein as compared to wild-type PI3Ka protein.
  • the compounds of the present disclosure bind to the PI3Ka protein in an allosteric pocket that is in proximity to the 1047 mutational hotspot.
  • Effectiveness of compounds of the disclosure can be determined by industry-accepted assays/ disease models according to standard practices of elucidating the same as described in the art and are found in the current general knowledge.
  • the present disclosure also provides a method of treating a disease or disorder in which PI3Ka activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.
  • Compounds of the present disclosure, or pharmaceutically acceptable salts thereof, may be administered alone as a sole therapy or can be administered in addition with one or more other substances and/or treatments. Such conjoint treatment may be achieved by w'ay of the simultaneous, sequential or separate administration of the individual components of the treatment.
  • therapeutic effectiveness may be enhanced by administration of an adjuvant (i.e. by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the individual is enhanced).
  • the benefit experienced by an individual may be increased by administering the compound of Formula (I) with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • the compound of the present disclosure need not be administered via the same route as other therapeutic agents, and may, because of different physical and chemical characteristics, be administered by a different route.
  • the compound of the disclosure may be administered orally to generate and maintain good blood levels thereof, while the other therapeutic agent may be administered intravenously.
  • the initial administration may be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.
  • a combination for use in the treatment of a disease in which PI3Ka activity is implicated comprising a compound of the disclosure as defined hereinbefore, or a pharmaceutically acceptable salt thereof, and another suitable agent.
  • composition which comprises a compound of the disclosure, or a pharmaceutically acceptable salt thereof, in combination with a suitable, in association with a pharmaceutically acceptable diluent or carrier.
  • compounds of Formula (I) and pharmaceutically acceptable salts thereof are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of modulators of PI3Ka activity in laboratory animals such as dogs, rabbits, monkeys, mini-pigs, rats and mice, as part of the search for new therapeutic agents.
  • the compounds of the disclosure or pharmaceutical compositions comprising these compounds may be administered to a subject by any convenient route of administration, whether systemically/ peripherally or topically (i.e., at the site of desired action).
  • Routes of administration include, but are not limited to, oral (e.g. by ingestion); buccal; sublingual, transdennal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray or powder), ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose), rectal (e.g., by suppository or enema); vaginal (e.g., by pessary'); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratrache
  • both neutral compounds and salts of the compounds of Formula (I) are synthesized and tested in the examples.
  • the neutral compounds of Formula (I) may be converted to the corresponding pharmaceutically acceptable salts of the compounds using routine techniques in the ait (e.g., by saponification of an ester to the carboxylic acid salt, or by hydrolyzing an amide to form a corresponding carboxylic acid and then converting the carboxylic acid to a carboxylic acid salt).
  • the salts (e.g., formate salt) of the compounds of Formula (I) may be converted to the corresponding neutral compounds using routine techniques in the art. (e.g., pH adjustment and, optionally, extraction (e.g., into an aqueous phase)).
  • Step 3 Synthesis of 8-bromo-2-chloro-6-m ethyl -quinoline-4-carbonyl chloride
  • a mixture of 8-bromo-2-hydroxy-6-methyl-quinoline-4-carboxylic acid (8.50 g, 30.1 mmol) in phosphorus oxychloride (85 mL) was stirred at 100 °C for 12 hr under nitrogen atmosphere. On completion, the reaction mixture was concentrated under reduced pressure to give 8-bromo-2-chloro-6-methyl-quinoline-4-carbonyl chloride (9.60 g, 30.1 mmol, 100%) as a brown oil.
  • Step 2 Synthesis of 8-bromo-6-ch1oro-2-hydroxyquinoline-4-carboxylic acid [0491] To a solution of 7-bromo-5-chloro-indoline-2, 3-dione (19 g, 72.9 mmol) in acetic acid (200 mL) was added malonic acid (22.7 g, 218 mmol). The mixture was stirred at 120 °C for 12 hr. On completion, the mixture was concentrated under reduced pressure.
  • Step 1 Synthesis of 8-bromo-6-chloro-2-morpholinoquinoline-4-carbonitrile [0499] To a solution of 8-bromo-2,6-dichloro-quinoline-4-carbonitrile (5.0 g, 16.6 mmol) in tXLV-dimethylformamide (50 ml) was added morpholine (2.16 g, 24.8 mmol) and jV-ethyl-;V, ⁇ V- diisopropylamine (6.42 g, 49.7 mmol), the mixture was stirred at 80 °C for 2 hr. On completion, the mixture was concentrated under reduced pressure.
  • reaction mixture was quenched with saturated sodium bicarbonate (500 mL), water (500 mL) and aqueous potassium fluoride solution (500 mL) 25 °C, and then extracted with ethyl acetate (400 mL x 3). The combined organic layers were washed with brine (550 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • Step 3 Synthesis of 8-(l-aminoethyl)-6-chloro-2-morpholinoquinoline-4-carbonitrile
  • methanol 10 mL
  • sodium cyanoborohydride 199 mg, 3.17 mmol
  • ammonium acetate 2.44 g, 31.7 mmol
  • Step 1 Synthesis of 8-bromo-3,6-dimethyl-2-morpholino-quinoline-4-carbonitrile
  • morpholine 397 mg, 4.57 mmol
  • 7V, ⁇ V-dimethy [formamide 2 mL
  • diisopropylethylamine 787 mg, 6.09 mmol
  • the reaction mixture mixture was diluted with water 50 mL and extracted with ethyl acetate (50 mL x 3).
  • Step 1 Synthesis of 8-(l-ydroxyethyl)-3,6-dimethyl-2-morpholino-quinoline-4-carbonitrile
  • 8-acetyl-3,6-dimethyl-2-morpholino-quinoline-4-carbonitrile 1.5 g, 4.85 mmol
  • sodium borohydride 7.33 mg, 19.3 mmol
  • the reaction mixture was stirred at 0 °C for 15 min.
  • the reaction mixture was quenched by addition ammonium chloride (15 mL) at 0 °C and extracted with ethyl acetate (30 mL x 2).
  • the reaction mixture was partitioned between ethyl acetate (1000 mL) and water (500 mL). The organic phase was separated, washed with brine (500 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (silicon dioxide, petroleum ether/ethyl aceuite 20/1 to 1 /I) to give 2-amino- 3-bromo-5-fluoro-A r -methoxy-jV-methyl-benzamide (22.3 g, 75.4 mmol, 92%) as a yellow 7 gum.
  • Step I Synthesis of l-(2-amino-5-f1uoro-phenyl)-2-cyclopropyl-ethanone
  • toluene 40 mL was added to a 500 mL three-necked flask (reactor B) under nitrogen atmosphere atmosphere and heated to 112 °C, then the reaction mixture of reactor A was added to reactor B at 112 °C slowly, at last stirred at 106 °C for 4 hr.
  • the reaction mixture was cooled to 25 °C, then quenched by water (80 mL) and stirred at 30 min, heated up to 55 °C and stirred at 55 °C for 20 min. Then the mixture was diluted with ethyl acetate (100 mL) and extracted with ethyl acetate (200 mL x 2).
  • Step 8 Synthesis of (/?,Z)-A’-(l-(4-cyano-3-cyclopropyl-6-fluoro-2-(t.etrahydro-2H-pyran-4- yl)quinolin-8-yl)ethylidene)-2-methylpropane-2-sulfinamide
  • Step 3 Synthesis of l-(2-bromo-5-fluoro-phenyl)piperidin-4-ol
  • sulfuric acid (3.67 g, 36.6 mmol) was dropped slowly into water (46 mL) at 0 ° C.
  • l-(2-amino-5-fluoro-phenyl)piperidin-4-ol (7 g, 33.2 mmol) was added slowly into the system and stirred, sodium nitrite (2.53 g, 36.6 mmol) was added into water (12 mL), stirred until clarification, and then slowly dropped into the raw material system while controlling the temperature to 0 to 10 ° C.
  • Step 4 Synthesis of [l-(2-bromO”5-fluoro-phenyl)-4-piperidyl]oxy”tert-butyl-dimethyl”Silane
  • 1-(2-bromo-5-f!uoro-phenyl)piperidin-4-ol 6.3 g, 22.9 mmol
  • N,N ⁇ dimethylformamide 63 mL
  • tert-butyl-chloro-dimethylsilane 5.20 g, 34.4 mmol
  • IH-imidazole 3.91 g, 57.4 mmol
  • reaction mixture was partitioned between water (200 mL) and ethyl acetate (500 mL), the organic phase was separated, washed with brine 500 mL (250 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue.
  • the residue was purified by column chromatography (silicon dioxide, petroleum ether/ethyl acetate ⁇ 100/0 to 1 : 1) to give [l-(2-bromo-5-fluoro-phenyl)-4-piperidyl]oxy-fer/-butyl-dimethyl-silane (7 g, 18.0 mmol, 78%) as a yellow oil.
  • Step 1 Synthesis of tert-butyl 2-((l-(6-chloro-4-cyano-2-morpholinoquinolin-8- y 1 )ethyl)ami no)benzoate
  • Step 1 Synthesis of 8-bromo-2-(4-(4-fluorophenyl)piperazin-l-yl)-6- methylquinoline-4-carbonitrile
  • Step 3 Synthesis of methyl 2-[l-[4-cyano-2”[4-(4-fluorophenyl)piperazin-l-yl]-6- methy I -8-quinoly 1 ] ethylami no] benzoate
  • Step 4 Synthesis of 2-((l-(4-Cyano-2-(4-(4-fluorophenyl)piperazin-l-yl)-6- m ethylquinoli n-8-yl)ethyl)amino)benzoic aci d
  • Step 1 Synthesis of tert-butyl 3-(i-methyl-lH-pyrazol-4-yl)-2,5-dihydro-lH-pyirole- 1 -carboxylate
  • Step 2 Synthesis of tert-butyl 3-(l-methyl-lH-pyrazol-4-yl)pyrrolidine-1 -carboxylate [0521] To a round-bottom flask was added wet palladium on activated carbon (200 mg, 10% loading) under nitrogen atmosphere. Then methanol (50 mL) was added slowly under nitrogen atmosphere followed by tert-butyl 3-(l-methylpyrazol-4-yl)-2,5-dihydropyrrole-l-carboxylate (2 g, 8.02 mmol). The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 psi) at 25 °C for 12 hr.
  • Step 4 Synthesis of 8-aromo-6-methy!-2-(3-(l-methyl-lH-pyrazol-4-yl)pyrrolidin-l- yl)quinoline-4-carbonitrile
  • Step 5 Synthesis of 8-acetyl-6-methyl-2-(3-(l-methyl-lH-pyrazol-4-yl)pyrrolidin-l- yl)quinoline-4 -carbonitrile
  • the mixture was stirred at 25 °C for 30 min.
  • the reaction was diluted with water (10 mL) and extracted with ethyl acetate ( 10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • Step 6 Synthesis of 8-(l -aminoethyl )-6-methyl-2-(3-(l-methyl-lH-pyrazol-4- yl)pyrrolidin- 1 -yl)quinoline-4-carbonitrile
  • 8-acetyl-6-methyl-2-[3-(l-methylpyrazol-4-yl)pyn’olidin-1- yl]quinoline-4-carbonitrile 230 mg, 640 pmol
  • ammonium acetate 493 mg, 6.40 mmol
  • the mixture was stirred at 120 °C for 1 hr under microwave irradiation.
  • the mixture was stirred at 110 °C for 2 hr under nitrogen atmosphere.
  • the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure.
  • Step 8 Synthesis of 2-((l-(4-cyano-6-methyl-2-(3-(l -methyl- lH-pyrazol-4- yl)pyrrolidin- 1 -yl)quinolin-8-yl)ethyl)amino)benzoic acid
  • Step 5 Synthesis of 4-(8-bromo-6-methyl-2-(piperidin-l-yl)quinolin-4-yl)morpholine
  • 8-bromo-4-chloro-6-methyl-2-(l-piperidyl)quinoline 800 mg, 2.36 mmol
  • morpholine 10 mL
  • p-toluenesulfonic acid 60.8 mg, 353 pmol
  • the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3).
  • Step 7 Synthesis of l-(6-methyl-4-morpholino-2-(piperidin-l-yl)quinolin-8-yl)ethan- I -amine
  • Step 8 Synthesis of methyl 2-((l-(6-methyl-4-morpholino-2-(piperidin-l-yl)quinolin- 8-yl)ethyl)amino)benzoate
  • the reaction mixture was degassed by bubbling nitrogen stream, then irradiated with two 34 W blue LED lamps (at approximately 7 cm away) as the light source to keep the reaction temperature at 25 °C for 2 hr.
  • the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL * 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
  • Step 9 Synthesis of 2-((l-(6-methyl-4-morpholino-2-(piperidin-l-yl)quinolin-8- yl)ethyl)amino)benzoic acid
  • the crude product was purified by prep-HPLC (column: Phenomenex C18 75 x 30 mm, 3 um; mobile phase: [w ? ater(formic acidj-acetonitrile]; B%: 22%-52%, 7 min) to give 2-[l-[6- methyl- 4-morpholino-2-(l-piperidyl)-8-quinolyl]ethylamino]benzoic acid ( 13.4 mg, 28,2 umol, 34%) as a white solid.
  • Step 1 Synthesis of 2-[l-(4-carbamoyl-6-chloro-2-morpholino-8- quinolyl)ethylamino]benzoic acid
  • reaction mixture was quenched with aqueous hydrochloric acid (1 M, 4.25 mL) at 25 °C and stirred for 0.5 hr.
  • aqueous hydrochloric acid (1 M, 4.25 mL) at 25 °C and stirred for 0.5 hr.
  • Step 4 Synthesis of methyl 2-((l-(4-cyano-2-(4-methoxypiperidin-l-yl)-6- methylquinolin-8-yl)ethyl)amino)benzoate
  • Step 5 Synthesis of 2-((l-(4-cyano-2-(4-methoxypiperidin-l-yl)-6-methylquinolin-8- y I )ethyl)ami no)benzoi c acid
  • Step 9 Synthesis of 8-(l-aminoethyl)-6-methyl-2-morpholinoquinoline-5-carbonitrile
  • 8-acetyl-6-methyl-2-morpholinoquinoline-5-carbonitrile (1 g, 3.39 mmol) in methanol (10 mL) was added ammonium acetate (2.61 g, 33.9 mmol) and sodium cyanoborohydride (212 mg, 3.39 mmol). Then the mixture was stirred at 60 °C for 1 hr.
  • Step 10 Synthesis of tert-butyl 2-((l-(5-cyano-6-methyl-2-morpholinoquinolin-8- yl)ethyl)amino)benzoate
  • reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
  • Step 3 Synthesis of 8-(1-aminoethyl)-6-methyl-2-(4-pyridyl)quinoline-4-carbonitrile
  • Step 3 To a solution of 8-acetyl-6-methyl-2-(4-pyridyl)quinoline-4-carbonitrile (300 mg, 1.04 mmol) in methanol (6 mL) was added ammonium acetate (1.61 g, 20.8 mmol) and sodium cyanoborohydride (65.6 mg, 1.04 mmol). The mixture was stirred at 60 °C for 1 hr. On completion, the reaction mixture was filtered and concentrated under reduced pressure.
  • Step 4 Synthesis of 2-[l-[4-cyano-6-methyl-2-(4-pyridyl)”8- qui noly I ] ethyl ami no] benzoi c acid
  • the crude product was purified by prep-HPLC (column: Waters Xbridge 150 x 25 mm x 5 um; mobile phase: [water( ammonium bicarbonate)-acetonitrile]; B%: 21%-51%, 9 min and column:3 Phenomenex Luna C18 75 x 30 mm x 3 um; mobile phase: [water(trifluoroacetic acid)-acetonitrile]; B%: 35%-55%, 8 min) to give 2-[l-[4-cyano-6-methyl-2-(4-pyridyl)-8- quinolyl]ethylaniino]benzoic acid (6.88 mg, 15.4 pmol, 14%) as a yellow solid.
  • Example 13 Preparation of 2-(l-[4-cyano-6-methyI-2-(morphoIin-4-yI)qninoIin-8- yl]ethyiamino)benzoie acid (Compound 1) [0597] Step 1. Synthesis of 8-bromo-6-methyl-2-(morpholin-4-yl)quinoline-4-carbonitrile [0598] 8-Bromo-2-chloro-6-methylquinoline-4-carbonitrile (3.0 g, 10.7 mmol) was dissolved in 40 mL of ethanol. To the solution were added morpholine (3.71 g, 42.6 mmol) and the mixture was left stirring overnight at 70 ° C.
  • Step 3 Synthesis of 8-(l -hydroxy ethyl)-6-methyl-2-(m orpholin-4-yl)quinoline-4- carbonitrile
  • Step 4 Synthesis of 2-( l-[4-cyano-6-m ethyl -2-(morpholin-4-yl)quinolin-8- y 1 ] ethyl aminojb enzoi c aci d
  • Example 14 and Example 15 Preparation of (R)-2-((l-(4-cyano-6-methyI-2- morpholinoquinolin-8"yl)ethyl)amino)benzoic acid and (S)-2-((l ⁇ (4”Cyano ⁇ 6-methyl-2 ⁇ morphoIinoquinolin-8-yI)ethyI)amino)benzoic add (Compounds 3 and 2) (stereochemistry
  • Step 4 Synthesis of 2-((l-(4-cyano-6-methyl-2-(piperidin-l-yl)quinolin-8- yl)ethyl)amino)benzoic acid
  • Example 18 and Example 19 Preparation of (R)-2-((l-(4-cyano-6-methyl-2-(piperidin-l- yl)quinolin ⁇ 8”yl)ethyl)amino)benzoic acid and (S)-2 ⁇ ((l-(4-cyano ⁇ 6”methyI ⁇ 2 ⁇ (piperidin ⁇ l-yl)quinolin-8-yl)ethyI)amino)benzoic acid (Compounds 18 and 19)
  • Step 1 Synthesis of tert-butyl 4-(8-bromo-4-cyano-6-methylquinolin-2-yl)piperazine- 1 -carboxylate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) et leurs promédicaments, sels pharmaceutiquement acceptables, compositions pharmaceutiques et procédés d'utilisation et des procédés pour leur préparation. Les composés de l'invention sont utiles pour moduler l'activité de PI3Kα et peuvent être utilisés dans le traitement de maladies ou de troubles dans lesquels l'activité de PI3Kα est impliquée, tels que le cancer.
PCT/US2023/071143 2022-07-27 2023-07-27 Dérivés de quinoléine substitués utiles comme inhibiteurs de pi3k WO2024026423A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369617P 2022-07-27 2022-07-27
US63/369,617 2022-07-27

Publications (1)

Publication Number Publication Date
WO2024026423A1 true WO2024026423A1 (fr) 2024-02-01

Family

ID=87696135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071143 WO2024026423A1 (fr) 2022-07-27 2023-07-27 Dérivés de quinoléine substitués utiles comme inhibiteurs de pi3k

Country Status (1)

Country Link
WO (1) WO2024026423A1 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2006103511A1 (fr) * 2005-03-31 2006-10-05 Pfizer Products Inc. Derives de cyclopentapyridine et de tetrahydroquinoline
WO2008118455A1 (fr) * 2007-03-23 2008-10-02 Amgen Inc. Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k)
WO2009134973A1 (fr) * 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quinoléines et analogues apparentés en tant que modulateurs de sirtuine
US20130023635A1 (en) * 2011-07-18 2013-01-24 Nifant Ev Ilya E Catalysts based on heterocyclic-8-anilinoquinoline ligands
WO2020132459A1 (fr) * 2018-12-20 2020-06-25 The Regents Of The University Of Michigan Composés de quinolinyl-pyrazine-carboxamide et utilisations associées
WO2021169990A1 (fr) * 2020-02-24 2021-09-02 泰励生物科技（上海）有限公司 Inhibiteurs de kras pour le traitement de cancers
WO2023078401A1 (fr) * 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Composés en tant qu'inhibiteurs de protéine kinase

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
WO2006103511A1 (fr) * 2005-03-31 2006-10-05 Pfizer Products Inc. Derives de cyclopentapyridine et de tetrahydroquinoline
WO2008118455A1 (fr) * 2007-03-23 2008-10-02 Amgen Inc. Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k)
WO2009134973A1 (fr) * 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quinoléines et analogues apparentés en tant que modulateurs de sirtuine
US20130023635A1 (en) * 2011-07-18 2013-01-24 Nifant Ev Ilya E Catalysts based on heterocyclic-8-anilinoquinoline ligands
WO2020132459A1 (fr) * 2018-12-20 2020-06-25 The Regents Of The University Of Michigan Composés de quinolinyl-pyrazine-carboxamide et utilisations associées
WO2021169990A1 (fr) * 2020-02-24 2021-09-02 泰励生物科技（上海）有限公司 Inhibiteurs de kras pour le traitement de cancers
WO2023078401A1 (fr) * 2021-11-05 2023-05-11 Fochon Biosciences, Ltd. Composés en tant qu'inhibiteurs de protéine kinase

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
"Methods in Enzymology", vol. 42, 1985, ACADEMIC PRESS, pages: 309 - 396
"Remington: the Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO.
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
AUSUBEL ET AL.: "Current Protocols in Moleculαr Biology", 2005, JOHN WILEY AND SONS, INC
CAHN ET AL., ANGEW. CHEM., vol. 78, 1966, pages 413
CAHN ET AL., AUGEW. CHEM. INTER. EDIT., vol. 5, 1966, pages 385
CAHN ET AL., EXPERIENTIA, vol. 12, 1956, pages 81
CAHN, J., CHEM. EDUC., vol. 41, 1964, pages 116
CAHNINGOLD, J. CHEM. SOC., 1951, pages 612
FAN HE ET AL: "Nickel halide complexes bearing 2-benzimidazolyl--arylquinoline-8-carboxamide derived ligands: Synthesis, characterization and catalytic behavior towards ethylene oligomerization and the vinyl polymerization of norbornene", JOURNAL OF ORGANOMETALLIC CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 712, 10 April 2012 (2012-04-10), pages 46 - 51, XP028509219, ISSN: 0022-328X, [retrieved on 20120420], DOI: 10.1016/J.JORGANCHEM.2012.04.013 *
FINGL ET AL., THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 1975
GREENE, 'Γ.W.WUTS, P.G. M.: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
H. BUNDGAARD ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 77, 1988, pages 285
H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, vol. 8, 1992, pages 1 - 38
H. BUNDGAARD: "A Textbook of Drug Design and Development", 1991, article "Design and Application of Pro-drugs", pages: 113 - 191
L. FIESERM. FIESER: "Fieser and Fieser's Reαgents for organic Synthesis", 1994, JOHN WILEY AND SONS
L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514
LOU SHAO-JIE ET AL: "Regiodivergent C-H Alkylation of Quinolines with Alkenes by Half-Sandwich Rare-Earth Catalysts", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 142, no. 42, 28 September 2020 (2020-09-28), pages 18128 - 18137, XP093096339, ISSN: 0002-7863, DOI: 10.1021/jacs.0c08362 *
N. KAKEYA ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692
P.G.M. WUTST.W. GREENE: "Greene's Protective Groups in Organic Synthesis", 2006, JOHN WILEY & SONS
PAGAR VINAYAK VISHNU ET AL: "Gold-catalyzed [alpha]-furanylations of quinoline N-oxides with alkenyldiazo carbonyl species", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 13, no. 22, 1 January 2015 (2015-01-01), pages 6166 - 6169, XP093096346, ISSN: 1477-0520, DOI: 10.1039/C5OB00696A *
PATANILAVOIE, CHERN. REV., vol. 96, 1996, pages 3147 - 3176
R. LAROCK: "Comprehensive Organic Trαnsformαtions", 1989, VCH PUBLISHERS
SAMBROOK ET AL.: "Molecular Cloning, A lαborαtory Mαnuαl", 2000, COLD SPRING HARBOR PRESS
SMITH, M. B.MARCH, J.: "March'.y Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2001, JOHN WILEY AND SONS
T. HIGUCHIV. STELLA: "Pro-Drugs as Novel Delivery Systems", AC.S. SYMPOSIUM SERIES, vol. 14

Similar Documents

Publication Publication Date Title
CN112142735B (zh) 一类稠和氰基吡啶类化合物、制备方法和用途
EP3555070B1 (fr) Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
ES2718495T3 (es) Inhibidores de la histona desmetilasa
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
CA3009669A1 (fr) Inhibiteurs de la tyrosine kinase de bruton
AU2016251253A1 (en) Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
WO2016173557A1 (fr) Composé ayant une activité d'inhibition de kinase, procédé de préparation et utilisations
CN111961034A (zh) 用作ret激酶抑制剂的化合物及其应用
CN112851663A (zh) 一种并杂环化合物及其用途
CA3194694A1 (fr) Derives d'acetamido-phenyltetrazole et leurs methodes d'utilisation
CN115322158A (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
WO2018001332A1 (fr) Composé ayant une activité inhibitrice contre l'isocitrate déshydrogénase mutante, son procédé de préparation et son utilisation
TW201900644A (zh) Fgfr4抑制劑及其制備與應用
WO2024026424A1 (fr) Dérivés de quinazolinone et utilisations associées
WO2023125841A1 (fr) COMPOSÉ HÉTÉROCYCLIQUE EN TANT QU'INHIBITEUR DE POLθ, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
WO2024026423A1 (fr) Dérivés de quinoléine substitués utiles comme inhibiteurs de pi3k
WO2022171088A1 (fr) Dérivé de pyrazolo[3,4-d]pyrimidin-3-one
CN114605390B (zh) 具有cdk激酶抑制活性的化合物、其药物组合物和用途
EP4225745A1 (fr) Dérivés acétamido-phénylbenzamides et leurs procédés d'utilisation
CN114907350A (zh) 一类含氮稠环类化合物、制备方法和用途
WO2024026419A1 (fr) Dérivés de quinoxaline en tant que modulateurs de pik3 alpha
JP2022528437A (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
CN116600808B (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
WO2022178256A1 (fr) Dérivés de 9h-purine substitués en position 6 et utilisations associées
WO2023083373A1 (fr) Composé utilisé comme inhibiteur de src

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23757496

Country of ref document: EP

Kind code of ref document: A1